ClinicalTrials.gg
CompletedNCT02045797Updated Nov 17, 2017Results posted

Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections

A Phase 2 interventional study of GSK2140944 Lyophile and GSK2140944 Capsules in Infections, Bacterial, sponsored by GlaxoSmithKline. Completed at 30 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-11-17.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing gepotidacin in Bacterial Infections — 1 open to participants now, 1 under way, none of them phase 3. gepotidacin · Bacterial Infections.

Enrollment
Largest of 11
126 · median 34
Started
2014
with 1 other
Phase 2
2 of 11
none open now
Registered
2nd of 11
by date
Lead sponsor
10 of 11
GlaxoSmithKline

Among the 11 studies testing gepotidacin in Bacterial Infections, this one has the largest enrollment, is one of 2 that started in 2014, is one of 2 in phase 2, and was the 2nd registered.

Bacterial Infections

585 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.

Browse Bacterial Infections studies →

Open to participants now

1 of the 11 studies testing gepotidacin in Bacterial Infections is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About gepotidacin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 57 Bacterial Infections studies recruiting now, 38 (67%) set no upper age limit and 14 (25%) stop at 75 or younger; 19 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing gepotidacin in Bacterial Infections, or all of them as a file.
02

Study summary

GSK2140944 belongs to a novel structural class of antibiotics - Bacterial Type II Topoisomerase Inhibitors (BTI). This is a Phase II, randomized, two-part, multicenter study designed to select the optimal dose by further characterizing the safety, tolerability and PK of GSK 2140944 and by evaluating efficacy in subjects requiring in-patient medical care to treat their suspected or confirmed Gram-positive acute bacterial skin and skin structure infections (ABSSSI). The selected dose will be used in future studies.

03

Conditions studied

  • Infections, Bacterial

Keywords

  • Dose ranging
  • Intravenous
  • Adaptive design
  • suspected or confirmed gram-positive acute bacterial skin and skin structure infection
  • Subjects
  • infection
  • Oral
  • GSK2140944
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject is an adult male at least 18 years of age or an adult female at least 18 years of age who meets one of the following criteria: A female of who is either 1) sexually inactive by abstinence, 2) whose sole male partner has been sterilized, or 3) uses a method with a failure rate of \< 1%. Females of child-bearing potential must not become pregnant during the study. A female of non child- bearing potential, which includes: Females who are surgically sterile with a documented hysterectomy and/or bilateral oophorectomy; Females with a documented tubal ligation. If the procedure was done hysteroscopically, the effectiveness of tubal occlusion must have been documented by hysterosalpingogram post procedure (typically 3 months after procedure); Females who are , defined as amenorrhoeic for greater than 1 year. For women whose menopausal status is in doubt, a documented previous confirmatory blood sample with follicle-stimulating hormone (FSH) > 40 milli-international units per milliliter (MIU/mL) and estradiol \<40 picograms per milliliter (\<140 picomole per liter) would need to be confirmed or they will be required to use one of the contraception methods.
  • The subject has a diagnosis of ABSSSI suspected or documented to be caused by Gram-positive pathogens that requires of intravenous (IV) antibiotic treatment for which subjects is willing to receive treatment in an in-patient setting for at least 2 days.. ABSSSI is defined as one of the following: Wound infection (traumatic or post-surgical): an infection involving skin and subcutaneous tissue, characterized by purulent drainage from a wound with surrounding redness, edema, and/or induration of a minimum surface area of 75 square centimeter (cm\^2) (e.g., the shortest distance of redness, edema, and/or induration extending at least 5 centimeter (cm) from the peripheral margin of the wound); Major cutaneous abscess: an infection characterized by a collection of pus within the dermis or deeper that is accompanied by redness, edema, and/or induration of a minimum surface area of 75 cm\^2 (e.g., the shortest distance of redness, edema, and/or induration extending at least 5 cm from the peripheral margin of the abscess). Cellulitis: a diffuse skin infection characterized by a spreading area of redness, edema, and/or induration of a minimum surface area of 75 cm\^2 Note: For subjects with more than one type of eligible lesion/wound or with multiple lesions of the same type, the investigator must clearly identify the lesion to be evaluated for study purposes. The identified lesion must be consistently chosen for assessment (including digital imaging) throughout the study. Incision and drainage (I\&D) of the lesion is permitted prior to the first dose of study medication and will be allowed, per protocol, up to 24 hours after the start of the first dose of study medication.
  • The subject has at least 1 additional sign or symptom of skin infection: fluctuation, heat/localized warmth, and pain/tenderness.
  • The subject has at least 1 systemic marker of infection at the time of screening: Lymphadenopathy (proximal to and within the drainage of the wound); Fever (>=38 degrees Celsius); white blood cells (WBC) elevation (>10000 /cubic millimetre [mm\^3] or >10% immature neutrophils regardless of WBC count); C-reactive protein > (ULN). Note: Systemic markers of infection are not required for subjects >70 years of age or for known or suspected (based on blood glucose levels) diabetics.
  • The subject has provided written, dated, and is willing and able to comply with the study protocol.

Exclusion criteria

Exclusion Criteria:

  • The subject is pregnant or nursing.
  • The subject has an immune-compromising illness; including known (HIV) infection or acquired immunodeficiency syndrome (AIDS), organ (including bone marrow) transplant recipients, hematological , and therapy, including high-dose (e.g., greater than 40mg prednisone or equivalent per day for greater than two weeks).
  • (BMI)>= 40.0 kilogram per square meter.
  • The subject has a serious underlying disease that could be imminently life-threatening, or is unlikely to survive for the duration of the study period.
  • The subject has a medical condition or requires medication that may be aggravated by inhibition of acetylcholinesterase, such as: the subject has poorly controlled asthma or at baseline, and, in the opinion, of the investigator is not stable on current therapy; the subject has acute severe pain, uncontrolled with conventional medical management; the subject has active peptic ulcer disease; the subject has parkinson's disease; the subject has myasthenia gravis; the subject has history of seizure disorder requiring medications for control. this does not include a history of childhood febrile seizures; the subject has any evidence of mechanical obstruction of the urinary or digestive tracts.
  • The subject has had a diagnosis of C. difficile infection (CDI) within 90 days of screening
  • The subject has history of seizure disorder requiring medications for control. This does not include a history of childhood febrile seizures.
  • The subject is a chronic abuser of alcohol or illicit substances such that it jeopardizes ability to comply with the protocol
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation
  • The subject has a PR Interval \<120 or >220 millisecond (msec)
  • interval (QTc) >450msec or QTc >480msec for subjects with bundle branch block. Note: The QTc is the QT interval corrected for heart rate according to either Bazett's formula (QTcB), Fridericia's formula (QTcF), or another method, machine or manual overread. The QTc should be based on single or averaged QTc values of triplicate ECGs obtained over a brief recording period. It is essential that the same method for calculating QTc that was used at a subjects baseline visit be used for that subject for all subsequent visits.
  • The subject has QRS duration \<70 or >120 msec.
  • The subject has pre-existing grade II atrioventricular block or higher, history of significant vasovagal and/or syncopal episodes, episodes of symptomatic bradycardia.
  • The subject has recent acute major blood loss with signs of hemodynamic instability.
  • The subject has liver function tests: (ALT) >2x ; alkaline phosphatase and >=1.5xULN (isolated bilirubin >1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
  • The subject has a current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones). Subjects with stable and/or will be eligible if they meet the liver function test criteria in criterion (ALT >2 × ULN; alkaline phosphatase and bilirubin ≥1.5 × ULN).

Note: All subjects will be screened for Hepatitis B surface antigen and Hepatitis C ribonucleic acid (RNA), but these results will not be used to determine subject eligibility or subject continuation in the study after enrollment.

  • The subject has any skin condition or skin infection listed below: Secondarily infected animal/human bite; Infected burn; Infections of chronic ulcerative lesions (including diabetic foot infections and peripheral vascular disease) that are likely to be polymicrobial in nature, or caused by Gram-negative or anaerobic organisms that are unlikely to have a Gram-positive pathogen as the causative agent, (Note: Subjects with diabetic foot infections or peripheral vascular disease are eligible if they have a qualifying ABSSSI but diabetic foot infections are not eligible lesions for investigation); An underlying skin disease, such as pre-existing eczematous dermatitis, with clinical evidence of secondary infection; Suspected or confirmed osteomyelitis; Suspected or confirmed septic arthritis; Uncomplicated ABSSSI such as simple abscess, impetiginous lesions, superficial cellulitis, furunculosis, carbunculosis, or folliculitis; Infected abdominal wounds unable to be surgically closed; Necrotizing fasciitis, rapidly necrotizing infections, gangrenous processes, or decubitus ulcer; An existing abscess that cannot be drained or a wound requiring significant surgical intervention that cannot be performed within 48 hours of initiation of study treatment; Skin infection known or suspected to be due to fungal, parasitic or viral pathogens; or known or suspected to be due to anaerobic bacterial pathogens or Pseudomonas aeruginosa (including ecthyma gangrenosum), or other Gram negative pathogens as the contributing pathogen; Skin infections complicated by the presence of prosthetic materials that are not to be removed such as central venous catheters, permanent cardiac pacemaker battery packs, or joint replacement prostheses.
  • The subject has received treatment with a systemic and/or topical antibacterial within 4 days of study entry; EXCEPT for any of following conditions: The subject received a single dose of a short-acting antibacterial (half-life less than 12 hours) drug prior to the first dose of study treatment; The subject has failed a previous ABSSSI regimen (i.e. at least 48 hours of treatment) and has documented lack of microbiological or clinical response to such therapy. A subject enrolled as a failure of a previous antibacterial treatment regimen must EITHER: Show worsening or lack of improvement or worsening in signs and symptoms of infection, including continued or worsening purulence, erythema with or without induration, fluctuation, heat/localized warmth, and pain/tenderness and/or continued or worsening systemic markers of infection OR show microbiological evidence of failure; The subject recently completed a treatment course with an antibacterial drug for an infection other than ABSSSI and the drug does not have antibacterial activity against bacterial pathogens that cause ABSSSI. (Note: topical antiseptics, chorhexidine, and alcohol and soaps for wound care are permitted). For the purposes of these criteria, the information may be obtained via a verbal interview with the subject or from the subject's medical records; information obtained via a verbal interview must be recorded in the subject's medical record.
  • The subject has known or suspected severe impairment of renal function, including a calculated (as calculated using the Cockroft-Gault method) of less than 30 millilitre per minute; requirement for peritoneal dialysis, hemodialysis, or hemofiltration; or oliguria (less than 20 millilitre urine output per hour over 24 hours).
  • The subject has known or suspected chronic neutropenia due to suppression of neutrophil production, or is anticipated to develop neutropenia during the course of the study (ie. new chemotherapy subject), with less than 1000 cells/mm\^3 (subjects with neutrophil counts as low as 500 cell/mm\^3 are eligible if the reduction is due entirely to the acute infectious process).
  • The subject has been previously enrolled in this study, or has previously been treated with GSK2140944.
  • The subject has participated in a clinical trial and has received an product within 30 days or 5 half-lives, whichever is longer
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
126 participants (actual)

Study arms

  • Experimental
    Treatment Group A

    Subject will receive GSK2140944 750mg IV every 12 hours (q12h; twice daily \[BID\]) on Day 1 and Day 2. Subject may switch to GSK2140944 1500mg orally (PO) q12h (BID) at investigator's decision or will continue to receive GSK2140944 750mg IV q12h (BID) from Day 3 to Day 10.

    Drug: GSK2140944 Lyophile · Drug: GSK2140944 Capsules

  • Experimental
    Treatment Group B

    Subject will receive GSK2140944 1000mg IV q12h (BID) on Day 1 and Day 2 . Subject may switch to GSK2140944 2000mg PO q12h (BID) at investigator's decision or will continue to receive GSK2140944 1000mg IV q12h (BID) from Day 3 to Day 10.

    Drug: GSK2140944 Lyophile · Drug: GSK2140944 Capsules

  • Experimental
    Treatment Group C

    Subject will receive GSK2140944 1000mg IV q8h (TID) on Day 1 and Day 2. Subject may switch to GSK2140944 2000mg PO q8h (TID) at investigator's decision or will continue to receive GSK2140944 1000mg IV q8h (TID) from Day 3 to Day 10.

    Drug: GSK2140944 Lyophile · Drug: GSK2140944 Capsules

Interventions

  • GSK2140944 Lyophile (pale yellow to grayish yellow cake) containing 750 mg of GSK2140944 (as free base) per vial for IV infusion.

  • GSK2140944 500 mg capsules will be supplied as pink hard gelatin capsule with no external markings filled with slightly agglomerated pale yellow to grayish yellow powder.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Composite of the Cure Rate as Measured by Clinical Response and Outcome at the Early Efficacy Visit Combined With Withdrawal Rate

    Cure rate and withdrawal rate data points was jointly assessed in a composite endpoint for all participants who received at least one dose of GSK2140944. Cure rate was defined as the percentage of participants exhibiting clinical improvement (=\>20% reduction in overall lesion area) at the early efficacy visit. Withdrawal rate was defined as the percentage of participants who withdrew from study treatment due to a drug-related adverse event (AE) at any point while on treatment.

    Time frame: Up to Day 3

Secondary outcomes

  1. Number of Participants With Clinical Response and Outcome at Early Efficacy Visit

    The assessment was used to determine whether to continue the participant in the study. Clinical response was assessed as either a clinical success or a clinical failure and the clinical outcome was subsequently determined programmatically, based on the clinical response. Clinical success was defined as a reduction in the total surface area of the lesion (as calculated by digital imaging) of \>=20% compared to Baseline and no administration of additional antibacterial therapy for the lesion under study. Clinical failure was defined as death of participant; increase or insufficient decrease (i.e., \<20%) in the area (as calculated by digital imaging) of the lesion or administration of non-trial antibacterial drug therapy for treatment of the lesion under study before the primary efficacy endpoint assessment. In addition when the participant refused to consent to clinical examination, the clinical outcome was assessed as unable to determine with subsequent response as failure.

    Time frame: Up to Day 3

  2. Number of Participants With Clinical Response and Outcome at the Post Therapy Visit (Day 12-18)

    The assessment was used to determine whether to continue the participant in the study. Clinical response was assessed as either a clinical success or a clinical failure and the clinical outcome was subsequently determined programmatically, based on the clinical response. Clinical success was defined as a reduction in the total surface area of the lesion (as calculated by digital imaging) of \>=20% compared to Baseline and no administration of additional antibacterial therapy for the lesion under study. Clinical failure was defined as death of participant; increase or insufficient decrease (i.e., \<20%) in the area (as calculated by digital imaging) of the lesion or administration of non-trial antibacterial drug therapy for treatment of the lesion under study before the primary efficacy endpoint assessment. In addition when the participant refused to consent to clinical examination, the clinical outcome was assessed as unable to determine with subsequent response as failure.

    Time frame: Day 12 to Day 18

  3. Number of Participants With Clinical Response and Outcome at the Final Follow up Visit (Day 21-28)

    The assessment was used to determine whether to continue the participant in the study. Clinical response was assessed as either a clinical success or a clinical failure and the clinical outcome was subsequently determined programmatically, based on the clinical response. Clinical success was defined as no increase in the total surface area of the lesion (as calculated by digital imaging) compared to post therapy visit and no further administration of antibacterial therapy for the lesion under study. Clinical recurrence was defined as death of participant; increase in the area of the lesion compared to post therapy visit or administration of additional antibacterial therapy for the lesion under study before the efficacy endpoint assessment for participants who were a clinical success at post therapy visit. In addition when the participant refused to consent to clinical examination, the clinical outcome was assessed as unable to determine with subsequent response as failure.

    Time frame: Day 21 to Day 28

  4. Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for Staphylococcus Aureus (SA) Pathogen in Lesion Sample

    The microbiological outcome was determined by comparing Baseline bacteriology lesion sample, to the culture results at early efficacy visit. The corresponding microbiological response (success or failure) by participant was then assigned. Microbiological eradication or persistence was defined as culture documented elimination or presence of Baseline pathogens from a bacteriology specimen taken at early efficacy visit respectively. Participant was considered to have outcome of presumed microbiological eradication or persistence when the participant was a clinical success or clinical failure and no bacteriological specimen was obtained at early efficacy visit respectively. When the determination of Baseline pathogen microbiological response could not be made, the outcome was considered as unable to determine. The data for SA in lesion sample has been presented.

    Time frame: Up to Day 3

  5. Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for Methicillin-resistant Staphylococcus Aureus (MRSA) in Lesion Sample

    The microbiological outcome was determined by comparing Baseline bacteriology lesion sample, to the culture results at early efficacy visit. The corresponding microbiological response (success or failure) by participant was then assigned. Microbiological eradication or persistence was defined as culture documented elimination or presence of Baseline pathogens from a bacteriology specimen taken at early efficacy visit respectively. Participant was considered to have outcome of presumed microbiological eradication or persistence when the participant was a clinical success or clinical failure and no bacteriological specimen was obtained at early efficacy visit respectively. When the determination of Baseline pathogen microbiological response could not be made, the outcome was considered as unable to determine. The data for MRSA in lesion sample has been presented.

    Time frame: Day 3

  6. Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for Methicillin-susceptible Staphylococcus Aureus (MSSA) in Lesion Sample

    The microbiological outcome was determined by comparing Baseline bacteriology lesion sample, to the culture results at early efficacy visit. The corresponding microbiological response (success or failure) by participant was then assigned. Microbiological eradication or persistence was defined as culture documented elimination or presence of Baseline pathogens from a bacteriology specimen taken at early efficacy visit respectively. Participant was considered to have outcome of presumed microbiological eradication or persistence when the participant was a clinical success or clinical failure and no bacteriological specimen was obtained at early efficacy visit respectively. When the determination of Baseline pathogen microbiological response could not be made, the outcome was considered as unable to determine. The data for MSSA in lesion sample has been presented.

    Time frame: Up to Day 3

  7. Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for Other Gram-positive Aerobic Pathogens in Lesion Sample

    The microbiological outcome was determined by comparing Baseline bacteriology lesion sample, to the culture results at early efficacy visit. The corresponding microbiological response (success or failure) by participant was then assigned. Microbiological eradication or persistence was defined as culture documented elimination or presence of Baseline pathogens from a bacteriology specimen taken at early efficacy visit respectively. Participant was considered to have outcome of presumed microbiological eradication or persistence when the participant was a clinical success or clinical failure and no bacteriological specimen was obtained at early efficacy visit respectively. When the determination of Baseline pathogen microbiological response could not be made, the outcome was considered as unable to determine. The data for other Gram-positive aerobic pathogens in lesion sample has been presented.

    Time frame: Up to Day 3

  8. Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for All Gram-positive Aerobic Pathogens in Lesion Sample

    The microbiological outcome was determined by comparing Baseline bacteriology lesion sample, to the culture results at early efficacy visit. The corresponding microbiological response (success or failure) by participant was then assigned. Microbiological eradication or persistence was defined as culture documented elimination or presence of Baseline pathogens from a bacteriology specimen taken at early efficacy visit respectively. Participant was considered to have outcome of presumed microbiological eradication or persistence when the participant was a clinical success or clinical failure and no bacteriological specimen was obtained at early efficacy visit respectively. When the determination of Baseline pathogen microbiological response could not be made, the outcome was considered as unable to determine. The data for all Gram-positive aerobic pathogens in lesion sample has been presented.

    Time frame: Up to Day 3

  9. Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for SA, MRSA and All Gram-positive Aerobic Pathogens in Blood Sample

    The microbiological outcome was determined by comparing Baseline bacteriology blood culture, to the culture results at early efficacy visit. The corresponding microbiological response (success or failure) by participant was then assigned. Microbiological eradication or persistence was defined as culture documented elimination or presence of Baseline pathogens from a bacteriology specimen taken at early efficacy visit respectively. Participant was considered to have outcome of presumed microbiological eradication or persistence when the participant was a clinical success or clinical failure and no bacteriological specimen was obtained at early efficacy visit respectively. When the determination of Baseline pathogen microbiological response could not be made, the outcome was considered as unable to determine. The data for SA, MRSA and all Gram-positive aerobic pathogens in blood sample has been presented.

    Time frame: Up to Day 3

  10. Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for SA Pathogen in Lesion Sample

    Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at post therapy visit. Corresponding response (success or failure) was then assigned. Microbiological eradication or persistence was culture documented elimination or presence of Baseline pathogens from a specimen taken at post therapy visit respectively. Presence of pathogens which was presumed to be eradicated at early efficacy visit was microbiological recurrence. Presumed microbiological eradication or persistence was when there was a clinical success or failure and no bacteriological specimen was obtained at post therapy respectively. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at post therapy visit for pathogens presumed eradicated at early efficacy visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for SA in lesion sample has been presented.

    Time frame: Day 12 to Day 18

  11. Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for MRSA in Lesion Sample

    Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at post therapy visit. Corresponding response (success or failure) was then assigned. Microbiological eradication or persistence was culture documented elimination or presence of Baseline pathogens from a specimen taken at post therapy visit respectively. Presence of pathogens which was presumed to be eradicated at early efficacy visit was microbiological recurrence. Presumed microbiological eradication or persistence was when there was a clinical success or failure and no bacteriological specimen was obtained post therapy respectively. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at post therapy visit for pathogens presumed eradicated at early efficacy visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for MRSA in lesion sample has been presented.

    Time frame: Day 12 to Day 18

  12. Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for MSSA in Lesion Sample

    Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at post therapy visit. Corresponding response (success or failure) was then assigned. Microbiological eradication or persistence was culture documented elimination or presence of Baseline pathogens from a specimen taken at post therapy visit respectively. Presence of pathogens which was presumed to be eradicated at early efficacy visit was microbiological recurrence. Presumed microbiological eradication or persistence was when there was a clinical success or failure and no bacteriological specimen was obtained post therapy respectively. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at post therapy visit for pathogens presumed eradicated at early efficacy visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for MSSA in lesion sample has been presented.

    Time frame: Day 12 to Day 18

  13. Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for Other Gram-positive Aerobic Pathogens in Lesion Sample

    Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at post therapy visit. Corresponding response (success or failure) was then assigned. Microbiological eradication or persistence was culture documented elimination or presence of Baseline pathogens from a specimen taken at post therapy visit respectively. Presence of pathogens which was presumed to be eradicated at early efficacy visit was microbiological recurrence. Presumed microbiological eradication or persistence was when there was a clinical success or failure and no bacteriological specimen was obtained post therapy respectively. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at post therapy visit for pathogens presumed eradicated at early efficacy visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine.

    Time frame: Day 12 to Day 18

  14. Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for All Gram-positive Aerobic Pathogens in Lesion Sample

    Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at post therapy visit. Corresponding response (success or failure) was then assigned. Microbiological eradication or persistence was culture documented elimination or presence of Baseline pathogens from a specimen taken at post therapy visit respectively. Presence of pathogens which was presumed to be eradicated at early efficacy visit was microbiological recurrence. Presumed microbiological eradication or persistence was when there was a clinical success or failure and no bacteriological specimen was obtained post therapy respectively. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at post therapy visit for pathogens presumed eradicated at early efficacy visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine.

    Time frame: Day 12 to Day 18

  15. Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for SA, MRSA and All Gram-positive Aerobic Pathogens in Blood Sample

    Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at post therapy visit. Corresponding response (success or failure) was then assigned. Microbiological eradication or persistence was culture documented elimination or presence of Baseline pathogens from a specimen taken at post therapy visit respectively. Presence of pathogens which was presumed to be eradicated at early efficacy visit was microbiological recurrence. Presumed microbiological eradication or persistence was when there was a clinical success or failure and no bacteriological specimen was obtained post therapy respectively. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at post therapy visit for pathogens presumed eradicated at early efficacy visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine.

    Time frame: Day 12 to Day 18

  16. Number of Pathogens With Microbiological Response and Outcome at Follow up Visit for SA Pathogen in Lesion Sample

    Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at final follow up visit. Corresponding response (success or failure) was then assigned. Microbiological eradication was culture documented elimination of Baseline pathogens from a bacteriology specimen taken at final follow up visit. Presumed microbiological eradication was when there was a clinical success and no bacteriological specimen was obtained at final follow up visit. Culture documented presence of Baseline pathogens in a bacteriology specimen taken at final follow up visit was microbiological recurrence. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at final follow up visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for SA pathogen in lesion sample has been presented.

    Time frame: Day 21 to Day 28

  17. Number of Pathogens With Microbiological Response and Outcome at Follow up Visit for MRSA in Lesion Sample

    Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at final follow up visit. Corresponding response (success or failure) was then assigned. Microbiological eradication was culture documented elimination of Baseline pathogens from a bacteriology specimen taken at final follow up visit. Presumed microbiological eradication was when there was a clinical success and no bacteriological specimen was obtained at final follow up visit. Culture documented presence of Baseline pathogens in a bacteriology specimen taken at final follow up visit was microbiological recurrence. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at final follow up visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for MRSA pathogen in lesion sample has been presented.

    Time frame: Day 21 to Day 28

  18. Number of Pathogens With Microbiological Response and Outcome at Follow up Visit for MSSA in Lesion Sample

    Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at final follow up visit. Corresponding response (success or failure) was then assigned. Microbiological eradication was culture documented elimination of Baseline pathogens from a bacteriology specimen taken at final follow up visit. Presumed microbiological eradication was when there was a clinical success and no bacteriological specimen was obtained at final follow up visit. Culture documented presence of Baseline pathogens in a bacteriology specimen taken at final follow up visit was microbiological recurrence. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at final follow up visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for MSSA pathogen in lesion sample has been presented.

    Time frame: Day 21 to Day 28

  19. Number of Pathogens With Microbiological Response and Outcome at Follow up Visit for Other Gram-positive Aerobic Pathogens in Lesion Sample

    Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at final follow up visit. Corresponding response (success or failure) was then assigned. Microbiological eradication was culture documented elimination of Baseline pathogens from a bacteriology specimen taken at final follow up visit. Presumed microbiological eradication was when there was a clinical success and no bacteriological specimen was obtained at final follow up visit. Culture documented presence of Baseline pathogens in a bacteriology specimen taken at final follow up visit was microbiological recurrence. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at final follow up visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for other Gram-positive aerobic pathogens in lesion sample has been presented.

    Time frame: Day 21 to Day 28

  20. Number of Pathogens With Microbiological Response and Outcome at Follow up Visit for All Gram-positive Aerobic Pathogens in Lesion Sample

    Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at final follow up visit. Corresponding response (success or failure) was then assigned. Microbiological eradication was culture documented elimination of Baseline pathogens from a bacteriology specimen taken at final follow up visit. Presumed microbiological eradication was when there was a clinical success and no bacteriological specimen was obtained at final follow up visit. Culture documented presence of Baseline pathogens in a bacteriology specimen taken at final follow up visit was microbiological recurrence. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at final follow up visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for all Gram-positive aerobic pathogens in lesion sample has been presented.

    Time frame: Day 21 to Day 28

  21. Number of Pathogens With Microbiological Response and Outcome at Follow up Visit for SA, MRSA and All Gram-positive Aerobic Pathogens in Blood Sample

    Microbiological outcome was determined by comparing Baseline blood culture, to culture results at final follow up visit. Corresponding response (success or failure) was then assigned. Microbiological eradication was culture documented elimination of Baseline pathogens from a bacteriology specimen taken at final follow up visit. Presumed microbiological eradication was when there was a clinical success and no bacteriological specimen was obtained at final follow up visit. Culture documented presence of Baseline pathogens in a bacteriology specimen taken at final follow up visit was microbiological recurrence. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at final follow up visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for SA, MRSA and all Gram-positive aerobic pathogens in lesion sample has been presented.

    Time frame: Day 21 to Day 28

  22. Pharmacokinetic (PK) Parameters (From GSK2140944 Plasma Concentration-time Data): Maximum Observed Concentration (Cmax) on IV Therapy

    Samples for assessment of PK parameter Cmax was done on at predose, 1, 2, 2.5, 3, 6, 12 hours post dose on Day 1 to 3. The first occurrence of the Cmax was determined directly from the raw concentration-time data. Data for participants while on IV therapy has been presented.

    Time frame: Predose, 1, 2, 2.5, 3, 6, 12 hours post dose on Day 1 to 3

  23. PK Parameters (From GSK2140944 Plasma Concentration-time Data): Cmax on Oral Dose Therapy

    Samples for assessment of PK parameter Cmax was done at Predose, 1, 2, 3 hours after first orally administered drug and one predose time point anytime from Day 7 to 10. The first occurrence of the Cmax was determined directly from the raw concentration-time data. Data for participants while on oral dose therapy has been presented.

    Time frame: Predose, 1, 2, 3 hours after first orally administered drug and Day 7 to 10 (predose)

  24. PK Parameters (From GSK2140944 Plasma Concentration-time Data): Time to Cmax (Tmax) on IV Therapy

    Samples for assessment of PK parameter tmax was done at predose, 1, 2, 2.5, 3, 6, 12 hours post dose on Day 1 to 3. The time at which Cmax was observed was determined directly from the raw concentration-time data. Data for participants while on IV therapy has been presented.

    Time frame: Predose, 1, 2, 2.5, 3, 6, 12 hours post dose on Day 1 to 3

  25. PK Parameters (From GSK2140944 Plasma Concentration-time Data): Tmax on Oral Dose Therapy

    Samples for assessment of PK parameter tmax was done at Predose, 1, 2, 3 hours after first orally administered drug and one predose time point anytime from Day 7 to 10. The time at which Cmax was observed was determined directly from the raw concentration-time data. Data for participants while on oral dose therapy has been presented.

    Time frame: Predose, 1, 2, 3 hours after first orally administered drug and Day 7 to 10 (predose)

  26. PK Parameters (From GSK2140944 Plasma Concentration-time Data): Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Time of the Last Quantifiable Concentration [AUC (0-t)] and AUC Over the Dosing Interval [AUC(0-tau)] on IV Therapy

    Samples for assessment of PK parameters AUClast and AUC0-tau was done at predose, 1, 2, 2.5, 3, 6, 12 hours post dose on Day 1 to 3. The AUC 0-t and AUC0-tau was determined using the linear trapezoidal rule for increasing concentrations and the logarithmic trapezoidal rule for decreasing concentrations. Data for participants while on IV therapy has been presented.

    Time frame: Predose, 1, 2, 2.5, 3, 6, 12 hours post dose on Day 1 to 3

  27. PK Parameters (From GSK2140944 Plasma Concentration-time Data): AUC (0-t) and AUC(0-tau) on Oral Dose Therapy

    Samples for assessment of PK parameters AUClast and AUC0-tau was done at predose, 1, 2, 3 hours after first orally administered drug and one predose time point anytime from Day 7 to 10. The AUC 0-t and AUC0-tau was determined using the linear trapezoidal rule for increasing concentrations and the logarithmic trapezoidal rule for decreasing concentrations. Data for participants while on oral dose therapy has been presented.

    Time frame: Predose, 1, 2, 3 hours after first orally administered drug and Day 7 to 10 (predose)

  28. Number of Participants Demonstrating a Decrease in GSK2140944 Susceptibility When Comparing Isolates Recovered From Baseline With Those From Any Time Post-Baseline Skin Specimens

    Reduction in susceptibility was defined as a \>=4-fold increase in minimum inhibitory concentration (MIC) or \>=6 millimeter decrease in zone size between an isolate obtained at Baseline and the same pathogen at subsequent visits.

    Time frame: Up to Day 28

  29. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, medically significant or all events of possible drug-induced liver injury with hyperbilirubinemia.

    Time frame: Up to Day 28

  30. Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

    SBP and DBP was measured with the participant in a supine or semi-supine position, having rested in that position for at least 10 minutes. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.

    Time frame: Baseline (Day 1) up to Day 28

  31. Change From Baseline in Pulse Rate

    Pulse rate was measured with the participant in a supine or semi-supine position, having rested in that position for at least 10 minutes. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.

    Time frame: Baseline (Day 1) up to Day 28

  32. Change From Baseline in Respiratory Rate

    Respiratory rate was measured with the participant in a supine or semi-supine position, having rested in that position for at least 10 minutes. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.

    Time frame: Baseline (Day 1) up to Day 28

  33. Change From Baseline in Vital Sign: Body Temperature

    Body temperature was measured with the participant in a supine or semi-supine position, having rested in that position for at least 10 minutes. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.

    Time frame: Baseline (Day 1) up to Day 28

  34. Number of Participants With Maximum Post-Baseline Electrocardiogram (ECG) Readings

    The 12-lead ECGs was obtained at Day 1, Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28 for corrected QT, using Fridericia formula (QTcF), corrected QT using Bazett's formula (QTcB) and QRS intervals. The number of participants with maximum post-baseline ECG value exceeding the following limits have been reported: QTcB/QTcF interval \> 450 and ≤ 480 millisecond (msec), QTcB/QTcF interval \> 480 and ≤ 500 msec, QTcB/QTcF interval \> 500 msec, QRS interval \< 70 msec and QRS interval \> 120 msec.

    Time frame: Up to Day 28

  35. Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT)

    Blood samples for assessment of clinical chemistry parameters of ALT, ALP, AST, FSH and GGT was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.

    Time frame: Baseline (Day 1) up to Day 28

  36. Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein

    Blood samples for assessment of clinical chemistry parameters of albumin and total protein was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.

    Time frame: Baseline (Day 1) up to Day 28

  37. Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate

    Blood samples for assessment of clinical chemistry parameters of bilirubin, creatinine, direct bilirubin and urate was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.

    Time frame: Baseline (Day 1) up to Day 28

  38. Change From Baseline in Clinical Chemistry Parameters: Calcium, Carbon Dioxide, Chloride, Glucose, Magnesium, Potassium, Sodium and Urea

    Blood samples for assessment of clinical chemistry parameters of calcium, carbon dioxide, chloride, glucose, magnesium, potassium, sodium and urea was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.

    Time frame: Baseline (Day 1) up to Day 28

  39. Change From Baseline in Clinical Chemistry Parameters: Creatinine Clearance, Estimated

    Blood samples for assessment of clinical chemistry parameter of estimated creatinine clearance was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.

    Time frame: Baseline (Day 1) up to Day 28

  40. Estradiol Values at Baseline

    Blood samples for assessment of clinical chemistry parameter of estradiol was collected at Baseline (Day 1). No post-baseline values were reported.

    Time frame: Baseline (Day 1)

  41. Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets

    Blood samples for assessment of hematology parameters of basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils and platelets was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.

    Time frame: Baseline (Day 1) up to Day 28

  42. Change From Baseline in Hematology Parameters: Erythrocyte Mean Corpuscular Hemoglobin Concentration (EMCHC) and Hemoglobin

    Blood samples for assessment of hematology parameters of EMCHC and hemoglobin was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.

    Time frame: Baseline (Day 1) up to Day 28

  43. Change From Baseline in Hematology Parameters: Erythrocyte Mean Corpuscular Hemoglobin (EMCH)

    Blood samples for assessment of hematology parameter of EMCH was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.

    Time frame: Baseline (Day 1) up to Day 28

  44. Change From Baseline in Hematology Parameters: Erythrocyte Mean Corpuscular Volume (EMCV)

    Blood samples for assessment of hematology parameter of EMCV was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.

    Time frame: Baseline (Day 1) up to Day 28

  45. Change From Baseline in Hematology Parameters: Erythrocytes

    Blood samples for assessment of hematology parameter of erythrocyte was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.

    Time frame: Baseline (Day 1) up to Day 28

  46. Change From Baseline in Hematology Parameters: Hematocrit

    Blood samples for assessment of hematology parameter of hematocrit was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.

    Time frame: Baseline (Day 1) up to Day 28

  47. Number of Participants With Abnormal Urinalysis Dipstick Results

    Samples for urinalysis assessment was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28 for Glucose, Ketones, Occult Blood, Protein and pH. Participants with abnormal urinalysis result was reported.

    Time frame: Up to day 28

07

Results

Posted Sep 21, 2017

Participant flow

This study was conducted at 13 centers in the United States from 24 March 2014 to 22 July 2015.

Participant flow — Overall Study
MilestoneGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
Started583925
Completed513224
Not completed771
Withdrew: Adverse event310
Withdrew: Lack of efficacy100
Withdrew: Lost to follow-up231
Withdrew: Physician decision010
Withdrew: Withdrawal by subject120

Outcome measures

PrimaryNumber of Participants With Composite of the Cure Rate as Measured by Clinical Response and Outcome at the Early Efficacy Visit Combined With Withdrawal Rate

Cure rate and withdrawal rate data points was jointly assessed in a composite endpoint for all participants who received at least one dose of GSK2140944. Cure rate was defined as the percentage of participants exhibiting clinical improvement (=\>20% reduction in overall lesion area) at the early efficacy visit. Withdrawal rate was defined as the percentage of participants who withdrew from study treatment due to a drug-related adverse event (AE) at any point while on treatment.

Time frame:
Up to Day 3
Reported as:
Count of participants · Participants
Number of Participants With Composite of the Cure Rate as Measured by Clinical Response and Outcome at the Early Efficacy Visit Combined With Withdrawal Rate
ParticipantsGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
Number Cured482823
Number Withdrawn100
SecondaryNumber of Participants With Clinical Response and Outcome at Early Efficacy Visit

The assessment was used to determine whether to continue the participant in the study. Clinical response was assessed as either a clinical success or a clinical failure and the clinical outcome was subsequently determined programmatically, based on the clinical response. Clinical success was defined as a reduction in the total surface area of the lesion (as calculated by digital imaging) of \>=20% compared to Baseline and no administration of additional antibacterial therapy for the lesion under study. Clinical failure was defined as death of participant; increase or insufficient decrease (i.e., \<20%) in the area (as calculated by digital imaging) of the lesion or administration of non-trial antibacterial drug therapy for treatment of the lesion under study before the primary efficacy endpoint assessment. In addition when the participant refused to consent to clinical examination, the clinical outcome was assessed as unable to determine with subsequent response as failure.

Time frame:
Up to Day 3
Reported as:
Count of participants · Participants
Number of Participants With Clinical Response and Outcome at Early Efficacy Visit
ParticipantsGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
Clinical Success482823
Clinical Failure772
Unable to Determine340
SecondaryNumber of Participants With Clinical Response and Outcome at the Post Therapy Visit (Day 12-18)

The assessment was used to determine whether to continue the participant in the study. Clinical response was assessed as either a clinical success or a clinical failure and the clinical outcome was subsequently determined programmatically, based on the clinical response. Clinical success was defined as a reduction in the total surface area of the lesion (as calculated by digital imaging) of \>=20% compared to Baseline and no administration of additional antibacterial therapy for the lesion under study. Clinical failure was defined as death of participant; increase or insufficient decrease (i.e., \<20%) in the area (as calculated by digital imaging) of the lesion or administration of non-trial antibacterial drug therapy for treatment of the lesion under study before the primary efficacy endpoint assessment. In addition when the participant refused to consent to clinical examination, the clinical outcome was assessed as unable to determine with subsequent response as failure.

Time frame:
Day 12 to Day 18
Reported as:
Count of participants · Participants
Number of Participants With Clinical Response and Outcome at the Post Therapy Visit (Day 12-18)
ParticipantsGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
Clinical Success523221
Clinical Failure111
Unable to Determine563
SecondaryNumber of Participants With Clinical Response and Outcome at the Final Follow up Visit (Day 21-28)

The assessment was used to determine whether to continue the participant in the study. Clinical response was assessed as either a clinical success or a clinical failure and the clinical outcome was subsequently determined programmatically, based on the clinical response. Clinical success was defined as no increase in the total surface area of the lesion (as calculated by digital imaging) compared to post therapy visit and no further administration of antibacterial therapy for the lesion under study. Clinical recurrence was defined as death of participant; increase in the area of the lesion compared to post therapy visit or administration of additional antibacterial therapy for the lesion under study before the efficacy endpoint assessment for participants who were a clinical success at post therapy visit. In addition when the participant refused to consent to clinical examination, the clinical outcome was assessed as unable to determine with subsequent response as failure.

Time frame:
Day 21 to Day 28
Reported as:
Count of participants · Participants
Number of Participants With Clinical Response and Outcome at the Final Follow up Visit (Day 21-28)
ParticipantsGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
Clinical Success502820
Clinical Failure111
Clinical Recurrence211
Unable to Determine593
SecondaryNumber of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for Staphylococcus Aureus (SA) Pathogen in Lesion Sample

The microbiological outcome was determined by comparing Baseline bacteriology lesion sample, to the culture results at early efficacy visit. The corresponding microbiological response (success or failure) by participant was then assigned. Microbiological eradication or persistence was defined as culture documented elimination or presence of Baseline pathogens from a bacteriology specimen taken at early efficacy visit respectively. Participant was considered to have outcome of presumed microbiological eradication or persistence when the participant was a clinical success or clinical failure and no bacteriological specimen was obtained at early efficacy visit respectively. When the determination of Baseline pathogen microbiological response could not be made, the outcome was considered as unable to determine. The data for SA in lesion sample has been presented.

Time frame:
Up to Day 3
Reported as:
Number · Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for Staphylococcus Aureus (SA) Pathogen in Lesion Sample
Number of pathogensGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
Microbiological Success, Eradication020
Microbiological Success, Presumed Eradication24179
Microbiological Failure, Persistence1132
Microbiological Failure, Presumed Persistence460
SecondaryNumber of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for Methicillin-resistant Staphylococcus Aureus (MRSA) in Lesion Sample

The microbiological outcome was determined by comparing Baseline bacteriology lesion sample, to the culture results at early efficacy visit. The corresponding microbiological response (success or failure) by participant was then assigned. Microbiological eradication or persistence was defined as culture documented elimination or presence of Baseline pathogens from a bacteriology specimen taken at early efficacy visit respectively. Participant was considered to have outcome of presumed microbiological eradication or persistence when the participant was a clinical success or clinical failure and no bacteriological specimen was obtained at early efficacy visit respectively. When the determination of Baseline pathogen microbiological response could not be made, the outcome was considered as unable to determine. The data for MRSA in lesion sample has been presented.

Time frame:
Day 3
Reported as:
Number · Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for Methicillin-resistant Staphylococcus Aureus (MRSA) in Lesion Sample
Number of pathogensGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
Microbiological Success, Eradication020
Microbiological Success, Presumed Eradication18104
Microbiological Failure, Persistence731
Microbiological Failure, Presumed Persistence450
SecondaryNumber of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for Methicillin-susceptible Staphylococcus Aureus (MSSA) in Lesion Sample

The microbiological outcome was determined by comparing Baseline bacteriology lesion sample, to the culture results at early efficacy visit. The corresponding microbiological response (success or failure) by participant was then assigned. Microbiological eradication or persistence was defined as culture documented elimination or presence of Baseline pathogens from a bacteriology specimen taken at early efficacy visit respectively. Participant was considered to have outcome of presumed microbiological eradication or persistence when the participant was a clinical success or clinical failure and no bacteriological specimen was obtained at early efficacy visit respectively. When the determination of Baseline pathogen microbiological response could not be made, the outcome was considered as unable to determine. The data for MSSA in lesion sample has been presented.

Time frame:
Up to Day 3
Reported as:
Number · Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for Methicillin-susceptible Staphylococcus Aureus (MSSA) in Lesion Sample
Number of pathogensGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
Microbiological Success, Presumed Eradication675
Microbiological Failure, Persistence401
Microbiological Failure, Presumed Persistence010
SecondaryNumber of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for Other Gram-positive Aerobic Pathogens in Lesion Sample

The microbiological outcome was determined by comparing Baseline bacteriology lesion sample, to the culture results at early efficacy visit. The corresponding microbiological response (success or failure) by participant was then assigned. Microbiological eradication or persistence was defined as culture documented elimination or presence of Baseline pathogens from a bacteriology specimen taken at early efficacy visit respectively. Participant was considered to have outcome of presumed microbiological eradication or persistence when the participant was a clinical success or clinical failure and no bacteriological specimen was obtained at early efficacy visit respectively. When the determination of Baseline pathogen microbiological response could not be made, the outcome was considered as unable to determine. The data for other Gram-positive aerobic pathogens in lesion sample has been presented.

Time frame:
Up to Day 3
Reported as:
Number · Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for Other Gram-positive Aerobic Pathogens in Lesion Sample
Number of pathogensGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
Microbiological Success, Eradication220
Microbiological Success, Presumed Eradication013
Microbiological Failure, Presumed Persistence110
Microbiological Failure, Unable to Determine100
SecondaryNumber of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for All Gram-positive Aerobic Pathogens in Lesion Sample

The microbiological outcome was determined by comparing Baseline bacteriology lesion sample, to the culture results at early efficacy visit. The corresponding microbiological response (success or failure) by participant was then assigned. Microbiological eradication or persistence was defined as culture documented elimination or presence of Baseline pathogens from a bacteriology specimen taken at early efficacy visit respectively. Participant was considered to have outcome of presumed microbiological eradication or persistence when the participant was a clinical success or clinical failure and no bacteriological specimen was obtained at early efficacy visit respectively. When the determination of Baseline pathogen microbiological response could not be made, the outcome was considered as unable to determine. The data for all Gram-positive aerobic pathogens in lesion sample has been presented.

Time frame:
Up to Day 3
Reported as:
Number · Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for All Gram-positive Aerobic Pathogens in Lesion Sample
Number of pathogensGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
Microbiological Success, Eradication240
Microbiological Success, Presumed Eradication241812
Microbiological Failure, Persistence1132
Microbiological Failure, Presumed Persistence570
Microbiological Failure, Unable to Determine100
SecondaryNumber of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for SA, MRSA and All Gram-positive Aerobic Pathogens in Blood Sample

The microbiological outcome was determined by comparing Baseline bacteriology blood culture, to the culture results at early efficacy visit. The corresponding microbiological response (success or failure) by participant was then assigned. Microbiological eradication or persistence was defined as culture documented elimination or presence of Baseline pathogens from a bacteriology specimen taken at early efficacy visit respectively. Participant was considered to have outcome of presumed microbiological eradication or persistence when the participant was a clinical success or clinical failure and no bacteriological specimen was obtained at early efficacy visit respectively. When the determination of Baseline pathogen microbiological response could not be made, the outcome was considered as unable to determine. The data for SA, MRSA and all Gram-positive aerobic pathogens in blood sample has been presented.

Time frame:
Up to Day 3
Reported as:
Number · Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for SA, MRSA and All Gram-positive Aerobic Pathogens in Blood Sample
Number of pathogensGepotidacin 750 mg q12h
SA, Microbiological Success, Eradication2
MRSA, Microbiological Success, Eradication2
Aerobic, Microbiological Success, Eradication2
SecondaryNumber of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for SA Pathogen in Lesion Sample

Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at post therapy visit. Corresponding response (success or failure) was then assigned. Microbiological eradication or persistence was culture documented elimination or presence of Baseline pathogens from a specimen taken at post therapy visit respectively. Presence of pathogens which was presumed to be eradicated at early efficacy visit was microbiological recurrence. Presumed microbiological eradication or persistence was when there was a clinical success or failure and no bacteriological specimen was obtained at post therapy respectively. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at post therapy visit for pathogens presumed eradicated at early efficacy visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for SA in lesion sample has been presented.

Time frame:
Day 12 to Day 18
Reported as:
Number · Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for SA Pathogen in Lesion Sample
Number of pathogensGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
Microbiological Success, Eradication310
Microbiological Success, Presumed Eradication32248
Microbiological Failure, Presumed Persistence321
Microbiological Failure, Presumed Recurrence112
SecondaryNumber of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for MRSA in Lesion Sample

Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at post therapy visit. Corresponding response (success or failure) was then assigned. Microbiological eradication or persistence was culture documented elimination or presence of Baseline pathogens from a specimen taken at post therapy visit respectively. Presence of pathogens which was presumed to be eradicated at early efficacy visit was microbiological recurrence. Presumed microbiological eradication or persistence was when there was a clinical success or failure and no bacteriological specimen was obtained post therapy respectively. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at post therapy visit for pathogens presumed eradicated at early efficacy visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for MRSA in lesion sample has been presented.

Time frame:
Day 12 to Day 18
Reported as:
Number · Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for MRSA in Lesion Sample
Number of pathogensGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
Microbiological Success, Eradication300
Microbiological Success, Presumed Eradication22174
Microbiological Failure, Presumed Persistence320
Microbiological Failure, Presumed Recurrence111
SecondaryNumber of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for MSSA in Lesion Sample

Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at post therapy visit. Corresponding response (success or failure) was then assigned. Microbiological eradication or persistence was culture documented elimination or presence of Baseline pathogens from a specimen taken at post therapy visit respectively. Presence of pathogens which was presumed to be eradicated at early efficacy visit was microbiological recurrence. Presumed microbiological eradication or persistence was when there was a clinical success or failure and no bacteriological specimen was obtained post therapy respectively. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at post therapy visit for pathogens presumed eradicated at early efficacy visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for MSSA in lesion sample has been presented.

Time frame:
Day 12 to Day 18
Reported as:
Number · Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for MSSA in Lesion Sample
Number of pathogensGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
Microbiological Success, Eradication010
Microbiological Success, Presumed Eradication1074
Microbiological Failure, Presumed Persistence001
Microbiological Failure, Presumed Recurrence001
SecondaryNumber of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for Other Gram-positive Aerobic Pathogens in Lesion Sample

Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at post therapy visit. Corresponding response (success or failure) was then assigned. Microbiological eradication or persistence was culture documented elimination or presence of Baseline pathogens from a specimen taken at post therapy visit respectively. Presence of pathogens which was presumed to be eradicated at early efficacy visit was microbiological recurrence. Presumed microbiological eradication or persistence was when there was a clinical success or failure and no bacteriological specimen was obtained post therapy respectively. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at post therapy visit for pathogens presumed eradicated at early efficacy visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine.

Time frame:
Day 12 to Day 18
Reported as:
Number · Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for Other Gram-positive Aerobic Pathogens in Lesion Sample
Number of pathogensGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
Microbiological Success, Presumed Eradication332
Microbiological Failure, Presumed Persistence010
Microbiological Failure, Presumed Recurrence101
SecondaryNumber of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for All Gram-positive Aerobic Pathogens in Lesion Sample

Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at post therapy visit. Corresponding response (success or failure) was then assigned. Microbiological eradication or persistence was culture documented elimination or presence of Baseline pathogens from a specimen taken at post therapy visit respectively. Presence of pathogens which was presumed to be eradicated at early efficacy visit was microbiological recurrence. Presumed microbiological eradication or persistence was when there was a clinical success or failure and no bacteriological specimen was obtained post therapy respectively. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at post therapy visit for pathogens presumed eradicated at early efficacy visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine.

Time frame:
Day 12 to Day 18
Reported as:
Number · Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for All Gram-positive Aerobic Pathogens in Lesion Sample
Number of pathogensGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
Microbiological Success, Eradication310
Microbiological Success, Presumed Eradication352710
Microbiological Failure, Presumed Persistence331
Microbiological Failure, Presumed Recurrence213
SecondaryNumber of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for SA, MRSA and All Gram-positive Aerobic Pathogens in Blood Sample

Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at post therapy visit. Corresponding response (success or failure) was then assigned. Microbiological eradication or persistence was culture documented elimination or presence of Baseline pathogens from a specimen taken at post therapy visit respectively. Presence of pathogens which was presumed to be eradicated at early efficacy visit was microbiological recurrence. Presumed microbiological eradication or persistence was when there was a clinical success or failure and no bacteriological specimen was obtained post therapy respectively. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at post therapy visit for pathogens presumed eradicated at early efficacy visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine.

Time frame:
Day 12 to Day 18
Reported as:
Number · Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for SA, MRSA and All Gram-positive Aerobic Pathogens in Blood Sample
Number of pathogensGepotidacin 750 mg q12h
SA, Microbiological Success, Presumed Eradication2
MRSA, Microbiological Success,Presumed Eradication2
Aerobic,MicrobiologicalSuccess,PresumedEradication2
SecondaryNumber of Pathogens With Microbiological Response and Outcome at Follow up Visit for SA Pathogen in Lesion Sample

Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at final follow up visit. Corresponding response (success or failure) was then assigned. Microbiological eradication was culture documented elimination of Baseline pathogens from a bacteriology specimen taken at final follow up visit. Presumed microbiological eradication was when there was a clinical success and no bacteriological specimen was obtained at final follow up visit. Culture documented presence of Baseline pathogens in a bacteriology specimen taken at final follow up visit was microbiological recurrence. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at final follow up visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for SA pathogen in lesion sample has been presented.

Time frame:
Day 21 to Day 28
Reported as:
Number · Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Follow up Visit for SA Pathogen in Lesion Sample
Number of pathogensGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
Microbiological Success, Eradication100
Microbiological Success, Presumed Eradication33218
Microbiological Failure, Presumed Recurrence140
Microbiological Failure, Unable to Determine433
SecondaryNumber of Pathogens With Microbiological Response and Outcome at Follow up Visit for MRSA in Lesion Sample

Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at final follow up visit. Corresponding response (success or failure) was then assigned. Microbiological eradication was culture documented elimination of Baseline pathogens from a bacteriology specimen taken at final follow up visit. Presumed microbiological eradication was when there was a clinical success and no bacteriological specimen was obtained at final follow up visit. Culture documented presence of Baseline pathogens in a bacteriology specimen taken at final follow up visit was microbiological recurrence. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at final follow up visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for MRSA pathogen in lesion sample has been presented.

Time frame:
Day 21 to Day 28
Reported as:
Number · Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Follow up Visit for MRSA in Lesion Sample
Number of pathogensGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
Microbiological Success, Eradication100
Microbiological Success, Presumed Eradication23144
Microbiological Failure, Presumed Recurrence130
Microbiological Failure, Unable to Determine431
SecondaryNumber of Pathogens With Microbiological Response and Outcome at Follow up Visit for MSSA in Lesion Sample

Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at final follow up visit. Corresponding response (success or failure) was then assigned. Microbiological eradication was culture documented elimination of Baseline pathogens from a bacteriology specimen taken at final follow up visit. Presumed microbiological eradication was when there was a clinical success and no bacteriological specimen was obtained at final follow up visit. Culture documented presence of Baseline pathogens in a bacteriology specimen taken at final follow up visit was microbiological recurrence. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at final follow up visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for MSSA pathogen in lesion sample has been presented.

Time frame:
Day 21 to Day 28
Reported as:
Number · Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Follow up Visit for MSSA in Lesion Sample
Number of pathogensGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
Microbiological Success, Presumed Eradication1074
Microbiological Failure, Presumed Recurrence010
Microbiological Failure, Unable to Determine002
SecondaryNumber of Pathogens With Microbiological Response and Outcome at Follow up Visit for Other Gram-positive Aerobic Pathogens in Lesion Sample

Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at final follow up visit. Corresponding response (success or failure) was then assigned. Microbiological eradication was culture documented elimination of Baseline pathogens from a bacteriology specimen taken at final follow up visit. Presumed microbiological eradication was when there was a clinical success and no bacteriological specimen was obtained at final follow up visit. Culture documented presence of Baseline pathogens in a bacteriology specimen taken at final follow up visit was microbiological recurrence. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at final follow up visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for other Gram-positive aerobic pathogens in lesion sample has been presented.

Time frame:
Day 21 to Day 28
Reported as:
Number · Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Follow up Visit for Other Gram-positive Aerobic Pathogens in Lesion Sample
Number of pathogensGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
Microbiological Success, Presumed Eradication322
Microbiological Failure, Presumed Recurrence010
Microbiological Failure, Unable to Determine111
SecondaryNumber of Pathogens With Microbiological Response and Outcome at Follow up Visit for All Gram-positive Aerobic Pathogens in Lesion Sample

Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at final follow up visit. Corresponding response (success or failure) was then assigned. Microbiological eradication was culture documented elimination of Baseline pathogens from a bacteriology specimen taken at final follow up visit. Presumed microbiological eradication was when there was a clinical success and no bacteriological specimen was obtained at final follow up visit. Culture documented presence of Baseline pathogens in a bacteriology specimen taken at final follow up visit was microbiological recurrence. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at final follow up visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for all Gram-positive aerobic pathogens in lesion sample has been presented.

Time frame:
Day 21 to Day 28
Reported as:
Number · Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Follow up Visit for All Gram-positive Aerobic Pathogens in Lesion Sample
Number of pathogensGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
Microbiological Success, Eradication100
Microbiological Success, Presumed Eradication362310
Microbiological Failure, Presumed Recurrence150
Microbiological Failure, Unable to Determine544
SecondaryNumber of Pathogens With Microbiological Response and Outcome at Follow up Visit for SA, MRSA and All Gram-positive Aerobic Pathogens in Blood Sample

Microbiological outcome was determined by comparing Baseline blood culture, to culture results at final follow up visit. Corresponding response (success or failure) was then assigned. Microbiological eradication was culture documented elimination of Baseline pathogens from a bacteriology specimen taken at final follow up visit. Presumed microbiological eradication was when there was a clinical success and no bacteriological specimen was obtained at final follow up visit. Culture documented presence of Baseline pathogens in a bacteriology specimen taken at final follow up visit was microbiological recurrence. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at final follow up visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for SA, MRSA and all Gram-positive aerobic pathogens in lesion sample has been presented.

Time frame:
Day 21 to Day 28
Reported as:
Number · Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Follow up Visit for SA, MRSA and All Gram-positive Aerobic Pathogens in Blood Sample
Number of pathogensGepotidacin 750 mg q12h
SA, Microbiological Success, Presumed Eradication2
MRSA,Microbiological Success,Presumed Eradication2
Aerobic,MicrobiologicalSuccess,PresumedEradication2
SecondaryPharmacokinetic (PK) Parameters (From GSK2140944 Plasma Concentration-time Data): Maximum Observed Concentration (Cmax) on IV Therapy

Samples for assessment of PK parameter Cmax was done on at predose, 1, 2, 2.5, 3, 6, 12 hours post dose on Day 1 to 3. The first occurrence of the Cmax was determined directly from the raw concentration-time data. Data for participants while on IV therapy has been presented.

Time frame:
Predose, 1, 2, 2.5, 3, 6, 12 hours post dose on Day 1 to 3
Reported as:
Geometric mean · Nanograms per milliliter
Pharmacokinetic (PK) Parameters (From GSK2140944 Plasma Concentration-time Data): Maximum Observed Concentration (Cmax) on IV Therapy
Nanograms per milliliterGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
Pharmacokinetic (PK) Parameters (From GSK2140944 Plasma Concentration-time Data): Maximum Observed Concentration (Cmax) on IV Therapy4590 ± 42.46059 ± 29.88848 ± 105.5
SecondaryPK Parameters (From GSK2140944 Plasma Concentration-time Data): Cmax on Oral Dose Therapy

Samples for assessment of PK parameter Cmax was done at Predose, 1, 2, 3 hours after first orally administered drug and one predose time point anytime from Day 7 to 10. The first occurrence of the Cmax was determined directly from the raw concentration-time data. Data for participants while on oral dose therapy has been presented.

Time frame:
Predose, 1, 2, 3 hours after first orally administered drug and Day 7 to 10 (predose)
Reported as:
Geometric mean · Nanograms per milliliter
PK Parameters (From GSK2140944 Plasma Concentration-time Data): Cmax on Oral Dose Therapy
Nanograms per milliliterGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
PK Parameters (From GSK2140944 Plasma Concentration-time Data): Cmax on Oral Dose Therapy2342 ± 84.74329 ± 67.83858 ± 94.1
SecondaryPK Parameters (From GSK2140944 Plasma Concentration-time Data): Time to Cmax (Tmax) on IV Therapy

Samples for assessment of PK parameter tmax was done at predose, 1, 2, 2.5, 3, 6, 12 hours post dose on Day 1 to 3. The time at which Cmax was observed was determined directly from the raw concentration-time data. Data for participants while on IV therapy has been presented.

Time frame:
Predose, 1, 2, 2.5, 3, 6, 12 hours post dose on Day 1 to 3
Reported as:
Median · Hours
PK Parameters (From GSK2140944 Plasma Concentration-time Data): Time to Cmax (Tmax) on IV Therapy
HoursGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
PK Parameters (From GSK2140944 Plasma Concentration-time Data): Time to Cmax (Tmax) on IV Therapy1.95 (0.00 to 3.05)1.90 (0.90 to 3.00)1.93 (0.00 to 3.00)
SecondaryPK Parameters (From GSK2140944 Plasma Concentration-time Data): Tmax on Oral Dose Therapy

Samples for assessment of PK parameter tmax was done at Predose, 1, 2, 3 hours after first orally administered drug and one predose time point anytime from Day 7 to 10. The time at which Cmax was observed was determined directly from the raw concentration-time data. Data for participants while on oral dose therapy has been presented.

Time frame:
Predose, 1, 2, 3 hours after first orally administered drug and Day 7 to 10 (predose)
Reported as:
Median · Hours
PK Parameters (From GSK2140944 Plasma Concentration-time Data): Tmax on Oral Dose Therapy
HoursGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
PK Parameters (From GSK2140944 Plasma Concentration-time Data): Tmax on Oral Dose Therapy3.00 (0.95 to 12.00)2.92 (1.02 to 12.00)2.98 (0.98 to 8.00)
SecondaryPK Parameters (From GSK2140944 Plasma Concentration-time Data): Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Time of the Last Quantifiable Concentration [AUC (0-t)] and AUC Over the Dosing Interval [AUC(0-tau)] on IV Therapy

Samples for assessment of PK parameters AUClast and AUC0-tau was done at predose, 1, 2, 2.5, 3, 6, 12 hours post dose on Day 1 to 3. The AUC 0-t and AUC0-tau was determined using the linear trapezoidal rule for increasing concentrations and the logarithmic trapezoidal rule for decreasing concentrations. Data for participants while on IV therapy has been presented.

Time frame:
Predose, 1, 2, 2.5, 3, 6, 12 hours post dose on Day 1 to 3
Reported as:
Geometric mean · Hour nanograms per milliliter
PK Parameters (From GSK2140944 Plasma Concentration-time Data): Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Time of the Last Quantifiable Concentration [AUC (0-t)] and AUC Over the Dosing Interval [AUC(0-tau)] on IV Therapy
Hour nanograms per milliliterGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
AUClast15992 ± 36.720904 ± 31.820851 ± 64.8
AUC0-tau16159 ± 36.320815 ± 31.721499 ± 66.9
SecondaryPK Parameters (From GSK2140944 Plasma Concentration-time Data): AUC (0-t) and AUC(0-tau) on Oral Dose Therapy

Samples for assessment of PK parameters AUClast and AUC0-tau was done at predose, 1, 2, 3 hours after first orally administered drug and one predose time point anytime from Day 7 to 10. The AUC 0-t and AUC0-tau was determined using the linear trapezoidal rule for increasing concentrations and the logarithmic trapezoidal rule for decreasing concentrations. Data for participants while on oral dose therapy has been presented.

Time frame:
Predose, 1, 2, 3 hours after first orally administered drug and Day 7 to 10 (predose)
Reported as:
Geometric mean · Hour nanograms per milliliter
PK Parameters (From GSK2140944 Plasma Concentration-time Data): AUC (0-t) and AUC(0-tau) on Oral Dose Therapy
Hour nanograms per milliliterGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
AUClast11965 ± 101.719308 ± 98.815923 ± 117.4
AUC0-tau14404 ± 78.224253 ± 65.419300 ± 77.9
SecondaryNumber of Participants Demonstrating a Decrease in GSK2140944 Susceptibility When Comparing Isolates Recovered From Baseline With Those From Any Time Post-Baseline Skin Specimens

Reduction in susceptibility was defined as a \>=4-fold increase in minimum inhibitory concentration (MIC) or \>=6 millimeter decrease in zone size between an isolate obtained at Baseline and the same pathogen at subsequent visits.

Time frame:
Up to Day 28
Reported as:
Count of participants · Participants
Number of Participants Demonstrating a Decrease in GSK2140944 Susceptibility When Comparing Isolates Recovered From Baseline With Those From Any Time Post-Baseline Skin Specimens
ParticipantsGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
Number of Participants Demonstrating a Decrease in GSK2140944 Susceptibility When Comparing Isolates Recovered From Baseline With Those From Any Time Post-Baseline Skin Specimens000
SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, medically significant or all events of possible drug-induced liver injury with hyperbilirubinemia.

Time frame:
Up to Day 28
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
Any AEs412518
Any SAEs110
SecondaryChange From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

SBP and DBP was measured with the participant in a supine or semi-supine position, having rested in that position for at least 10 minutes. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.

Time frame:
Baseline (Day 1) up to Day 28
Reported as:
Mean · Millimeters of mercury
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Millimeters of mercuryGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
SBP, ON IV TREATMENT/DAY 1-2.9 ± 15.07-1.7 ± 13.90-2.4 ± 9.43
SBP, ON IV TREATMENT/DAY 2-4.8 ± 14.630.3 ± 13.55-1.9 ± 9.73
SBP, ON IV TREATMENT/DAY 3-1.7 ± 14.571.6 ± 11.25-2.1 ± 13.88
SBP, ON IV TREATMENT/DAY 4-3.2 ± 14.25-1.2 ± 17.11-22.0 ± 31.11
SBP, ON IV TREATMENT/DAY 5-4.8 ± 17.90-1.6 ± 31.01—
SBP, ON IV TREATMENT/DAY 6-8.0 ± 14.60-2.7 ± 14.83—
SBP, ON IV TREATMENT/DAY 7-17.0 ± 16.572.3 ± 32.39—
SBP, ON IV TREATMENT/DAY 8-10.3 ± 29.87——
SBP, ON IV TREATMENT/DAY 912.0 ± 1.41——
SBP, ON IV TREATMENT/DAY 106.0 ± NA——
SBP, ORAL - FIRST DAY1.6 ± 13.362.3 ± 13.86-3.7 ± 13.59
SBP, ORAL - DAY 7-102.8 ± 9.141.9 ± 10.55-0.9 ± 17.91
SBP, POST THERAPY DAY 12-18-0.1 ± 13.714.5 ± 11.334.1 ± 11.09
SBP, FOLLOW UP DAY 21-282.5 ± 12.872.1 ± 12.241.7 ± 15.60
SBP, POST DOSE DAY 3-10-23.0 ± NA——
DBP, ON IV TREATMENT/DAY 1-3.1 ± 10.28-2.9 ± 10.97-2.3 ± 9.21
DBP, ON IV TREATMENT/DAY 2-3.5 ± 10.84-0.9 ± 9.26-2.1 ± 9.77
DBP, ON IV TREATMENT/DAY 3-4.5 ± 10.98-0.9 ± 9.93-3.5 ± 14.74
DBP, ON IV TREATMENT/DAY 4-1.9 ± 12.190.6 ± 11.19-12.5 ± 30.41
DBP, ON IV TREATMENT/DAY 5-0.9 ± 13.66-2.0 ± 14.83—
DBP, ON IV TREATMENT/DAY 6-1.4 ± 11.75-9.2 ± 15.38—
DBP, ON IV TREATMENT/DAY 7-1.6 ± 23.37-13.8 ± 19.09—
DBP, ON IV TREATMENT/DAY 8-0.3 ± 18.50——
DBP, ON IV TREATMENT/DAY 913.0 ± 21.21——
DBP, ON IV TREATMENT/DAY 108.0 ± NA——
DBP, ORAL - FIRST DAY0.0 ± 11.26-1.0 ± 8.44-3.4 ± 12.84
DBP, ORAL - DAY 7-10-1.2 ± 9.120.4 ± 8.130.0 ± 11.13
DBP, POST THERAPY DAY 12-182.2 ± 9.182.3 ± 8.003.5 ± 12.23
DBP, FOLLOW UP DAY 21-282.3 ± 11.000.0 ± 9.941.2 ± 13.44
DBP, POST DOSE DAY 3-10-5.0 ± NA——
SecondaryChange From Baseline in Pulse Rate

Pulse rate was measured with the participant in a supine or semi-supine position, having rested in that position for at least 10 minutes. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.

Time frame:
Baseline (Day 1) up to Day 28
Reported as:
Mean · Beats per minute
Change From Baseline in Pulse Rate
Beats per minuteGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
ON IV TREATMENT/DAY 1-4.5 ± 11.38-3.8 ± 10.66-2.0 ± 10.39
ON IV TREATMENT/DAY 2-6.3 ± 14.31-1.2 ± 10.66-5.2 ± 10.78
ON IV TREATMENT/DAY 3-7.5 ± 14.08-6.6 ± 10.28-7.1 ± 12.62
ON IV TREATMENT/DAY 4-11.3 ± 18.27-5.5 ± 10.37-7.0 ± 12.73
ON IV TREATMENT/DAY 5-15.1 ± 22.36-9.9 ± 13.50—
ON IV TREATMENT/DAY 6-16.9 ± 21.60-11.0 ± 10.22—
ON IV TREATMENT/DAY 7-28.4 ± 33.57-18.0 ± 16.75—
ON IV TREATMENT/DAY 8-32.3 ± 15.63——
ON IV TREATMENT/DAY 9-45.5 ± 31.82——
ON IV TREATMENT/DAY 10-68.0 ± NA——
ORAL - FIRST DAY-6.7 ± 15.43-5.6 ± 13.47-7.0 ± 11.45
ORAL - DAY 7-10-1.6 ± 12.35-1.8 ± 10.53-5.7 ± 15.33
POST THERAPY DAY 12-18-1.6 ± 15.022.7 ± 13.38-7.0 ± 16.34
FOLLOW UP DAY 21-28-1.6 ± 13.59-1.1 ± 10.09-2.5 ± 17.10
POST DOSE DAY 3-10-15.0 ± NA——
SecondaryChange From Baseline in Respiratory Rate

Respiratory rate was measured with the participant in a supine or semi-supine position, having rested in that position for at least 10 minutes. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.

Time frame:
Baseline (Day 1) up to Day 28
Reported as:
Mean · Breaths per minute
Change From Baseline in Respiratory Rate
Breaths per minuteGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
ON IV TREATMENT/DAY 1-0.4 ± 2.66-0.1 ± 1.640.7 ± 2.90
ON IV TREATMENT/DAY 20.1 ± 2.28-0.3 ± 2.37-0.5 ± 1.73
ON IV TREATMENT/DAY 30.3 ± 2.80-0.6 ± 1.58-0.3 ± 2.17
ON IV TREATMENT/DAY 4-0.1 ± 1.78-1.0 ± 1.94-1.0 ± 1.41
ON IV TREATMENT/DAY 5-0.4 ± 2.22-0.7 ± 1.25—
ON IV TREATMENT/DAY 6-0.1 ± 2.33-0.8 ± 1.47—
ON IV TREATMENT/DAY 7-1.2 ± 2.68-1.0 ± 1.15—
ON IV TREATMENT/DAY 8-1.3 ± 4.16——
ON IV TREATMENT/DAY 9-4.0 ± 2.83——
ON IV TREATMENT/DAY 10-6.0 ± NA——
ORAL - FIRST DAY0.4 ± 2.330.3 ± 1.660.2 ± 1.92
ORAL - DAY 7-10-0.2 ± 2.39-0.1 ± 2.35-0.2 ± 2.04
POST THERAPY DAY 12-180.0 ± 2.94-0.3 ± 1.97-0.4 ± 2.02
FOLLOW UP DAY 21-28-0.6 ± 2.81-0.3 ± 2.04-0.5 ± 1.78
POST DOSE DAY 3-10-2.0 ± NA——
SecondaryChange From Baseline in Vital Sign: Body Temperature

Body temperature was measured with the participant in a supine or semi-supine position, having rested in that position for at least 10 minutes. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.

Time frame:
Baseline (Day 1) up to Day 28
Reported as:
Mean · Celcius
Change From Baseline in Vital Sign: Body Temperature
CelciusGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
ON IV TREATMENT/DAY 1-0.126 ± 0.6632-0.053 ± 0.4114-0.172 ± 0.4208
ON IV TREATMENT/DAY 2-0.195 ± 0.6058-0.173 ± 0.4642-0.400 ± 0.5672
ON IV TREATMENT/DAY 3-0.393 ± 0.5986-0.308 ± 0.4216-0.456 ± 0.7548
ON IV TREATMENT/DAY 4-0.476 ± 0.7242-0.455 ± 0.5610-0.550 ± 0.2121
ON IV TREATMENT/DAY 5-0.662 ± 0.8412-0.521 ± 0.6013—
ON IV TREATMENT/DAY 6-1.080 ± 0.9589-0.842 ± 1.0670—
ON IV TREATMENT/DAY 7-1.400 ± 1.1726-0.738 ± 0.8901—
ON IV TREATMENT/DAY 8-0.533 ± 0.6110——
ON IV TREATMENT/DAY 9-0.800 ± 0.7071——
ON IV TREATMENT/DAY 10-1.100 ± NA——
ORAL - FIRST DAY-0.398 ± 0.8149-0.304 ± 0.7005-0.608 ± 0.7593
ORAL - DAY 7-10-0.498 ± 0.6496-0.468 ± 0.6417-0.635 ± 0.8483
POST THERAPY DAY 12-18-0.485 ± 0.7579-0.439 ± 0.6764-0.645 ± 0.9379
FOLLOW UP DAY 21-28-0.441 ± 0.7579-0.375 ± 0.7255-0.604 ± 0.8891
POST DOSE DAY 3-10-0.200 ± NA——
SecondaryNumber of Participants With Maximum Post-Baseline Electrocardiogram (ECG) Readings

The 12-lead ECGs was obtained at Day 1, Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28 for corrected QT, using Fridericia formula (QTcF), corrected QT using Bazett's formula (QTcB) and QRS intervals. The number of participants with maximum post-baseline ECG value exceeding the following limits have been reported: QTcB/QTcF interval \> 450 and ≤ 480 millisecond (msec), QTcB/QTcF interval \> 480 and ≤ 500 msec, QTcB/QTcF interval \> 500 msec, QRS interval \< 70 msec and QRS interval \> 120 msec.

Time frame:
Up to Day 28
Reported as:
Count of participants · Participants
Number of Participants With Maximum Post-Baseline Electrocardiogram (ECG) Readings
ParticipantsGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
QTcB, Maximum Post-Baseline, <=45027159
QTcB, Maximum Post-Baseline, <=450 and <=480281911
QTcB, Maximum Post-Baseline, >480 and <=500343
QTcB, Maximum Post-Baseline, >500002
QTcF, Maximum Post-Baseline, <=450472817
QTcF, Maximum Post-Baseline, <=450 and <=48011108
QRS, Maximum Post-Baseline, 70 - 120563623
QRS, Maximum Post-Baseline, >120222
SecondaryChange From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT)

Blood samples for assessment of clinical chemistry parameters of ALT, ALP, AST, FSH and GGT was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.

Time frame:
Baseline (Day 1) up to Day 28
Reported as:
Mean · International units per liter
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT)
International units per literGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
ALT, ON IV TREATMENT/DAY 2-1.9 ± 5.40-1.0 ± 4.672.3 ± 14.57
ALT, ON IV TREATMENT/DAY 31.2 ± 14.631.4 ± 9.711.2 ± 6.30
ALT, ON IV TREATMENT/DAY 4—14.0 ± NA—
ALT, ON IV TREATMENT/DAY 59.3 ± 18.272.8 ± 9.89—
ALT, ON IV TREATMENT/DAY 737.5 ± 19.0918.5 ± 9.19—
ALT, ORAL - FIRST DAY3.6 ± 17.524.1 ± 11.585.7 ± 11.57
ALT, ORAL - DAY 7-106.6 ± 15.757.3 ± 17.746.3 ± 12.60
ALT, POST THERAPY DAY 12-1812.8 ± 35.548.3 ± 21.904.2 ± 16.02
ALT, FOLLOW UP DAY 21-2836.2 ± 53.7827.8 ± 39.039.3 ± 4.62
ALT, POST DOSE DAY 3-1022.0 ± NA——
ALP, ON IV TREATMENT/DAY 2-1.4 ± 11.52-1.3 ± 12.27-4.0 ± 12.23
ALP, ON IV TREATMENT/DAY 31.8 ± 18.975.7 ± 14.17-0.4 ± 6.17
ALP, ON IV TREATMENT/DAY 4—15.0 ± NA—
ALP, ON IV TREATMENT/DAY 5-0.3 ± 13.015.0 ± 11.49—
ALP, ON IV TREATMENT/DAY 73.0 ± 22.6310.0 ± 21.21—
ALP, ORAL - FIRST DAY5.1 ± 19.304.0 ± 17.38-0.4 ± 11.32
ALP, ORAL - DAY 7-103.8 ± 13.212.2 ± 19.16-0.1 ± 11.17
ALP, POST THERAPY DAY 12-18-0.8 ± 15.970.1 ± 16.16-1.8 ± 11.72
ALP, FOLLOW UP DAY 21-284.6 ± 19.4915.6 ± 20.84-2.0 ± 3.61
ALP, POST DOSE DAY 3-1017.0 ± NA——
AST, ON IV TREATMENT/DAY 2-1.1 ± 6.580.7 ± 7.032.0 ± 10.85
AST, ON IV TREATMENT/DAY 31.6 ± 12.476.2 ± 22.306.9 ± 18.84
AST, ON IV TREATMENT/DAY 4—22.0 ± NA—
AST, ON IV TREATMENT/DAY 57.4 ± 17.954.2 ± 13.01—
AST, ON IV TREATMENT/DAY 723.0 ± NA22.0 ± 0.00—
AST, ORAL - FIRST DAY4.3 ± 13.3434 ± 13.526.3 ± 17.83
AST, ORAL - DAY 7-106.7 ± 12.086.8 ± 13.932.3 ± 17.44
AST, POST THERAPY DAY 12-1810.9 ± 18.989.0 ± 15.530.8 ± 19.05
AST, FOLLOW UP DAY 21-2816.2 ± 22.1522.6 ± 29.905.3 ± 2.52
AST, POST DOSE DAY 3-109.0 ± NA——
GGT, ON IV TREATMENT/DAY 2-1.5 ± 7.68-1.9 ± 8.10-1.4 ± 10.15
GGT, ON IV TREATMENT/DAY 31.7 ± 18.663.8 ± 12.231.9 ± 5.16
GGT, ON IV TREATMENT/DAY 4—-4.0 ± NA—
GGT, ON IV TREATMENT/DAY 53.3 ± 21.70-2.5 ± 5.21—
GGT, ON IV TREATMENT/DAY 725.5 ± 0.71-3.0 ± 12.73—
GGT, ORAL - FIRST DAY3.3 ± 20.164.5 ± 16.25-1.1 ± 10.95
GGT, ORAL - DAY 7-103.6 ± 17.067.5 ± 19.89-2.2 ± 14.75
GGT, POST THERAPY DAY 12-183.0 ± 15.605.3 ± 21.08-3.9 ± 16.80
GGT, FOLLOW UP DAY 21-286.0 ± 13.5664.0 ± 89.913.0 ± NA
GGT, POST DOSE DAY 3-1039.0 ± NA——
SecondaryChange From Baseline in Clinical Chemistry Parameters: Albumin and Protein

Blood samples for assessment of clinical chemistry parameters of albumin and total protein was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.

Time frame:
Baseline (Day 1) up to Day 28
Reported as:
Mean · Gram per liter
Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein
Gram per literGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
Albumin, ON IV TREATMENT/DAY 2-2.4 ± 3.57-1.1 ± 2.93-2.9 ± 3.34
Albumin, ON IV TREATMENT/DAY 3-1.7 ± 4.09-0.6 ± 3.52-2.0 ± 3.46
Albumin, ON IV TREATMENT/DAY 4—1.0 ± NA—
Albumin, ON IV TREATMENT/DAY 5-1.1 ± 4.09-1.5 ± 3.62—
Albumin, ON IV TREATMENT/DAY 74.0 ± 8.49-0.5 ± 0.71—
Albumin, ORAL - FIRST DAY0.0 ± 3.39-0.2 ± 3.37-0.9 ± 2.86
Albumin, ORAL - DAY 7-101.8 ± 3.581.4 ± 3.041.2 ± 2.51
Albumin, POST THERAPY DAY 12-182.1 ± 3.812.8 ± 4.410.8 ± 3.61
Albumin, FOLLOW UP DAY 21-282.8 ± 2.360.3 ± 2.220.0 ± NA
Albumin, POST DOSE DAY 3-10-4.0 ± NA——
Protein, ON IV TREATMENT/DAY 2-3.2 ± 6.36-1.9 ± 5.86-5.2 ± 6.28
Protein, ON IV TREATMENT/DAY 3-1.6 ± 7.04-0.3 ± 5.88-4.8 ± 6.59
Protein, ON IV TREATMENT/DAY 4—0.0 ± NA—
Protein, ON IV TREATMENT/DAY 5-0.5 ± 8.22-2.3 ± 7.34—
Protein, ON IV TREATMENT/DAY 75.5 ± 13.44-1.0 ± 8.49—
Protein, ORAL - FIRST DAY1.4 ± 5.96-0.2 ± 6.82-1.2 ± 5.05
Protein, ORAL - DAY 7-103.1 ± 6.952.2 ± 5.880.5 ± 3.59
Protein, POST THERAPY DAY 12-182.9 ± 7.213.1 ± 9.14-1.1 ± 5.93
Protein, FOLLOW UP DAY 21-285.0 ± 5.290.8 ± 5.06-7.0 ± NA
Protein, POST DOSE DAY 3-10-3.0 ± NA——
SecondaryChange From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate

Blood samples for assessment of clinical chemistry parameters of bilirubin, creatinine, direct bilirubin and urate was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.

Time frame:
Baseline (Day 1) up to Day 28
Reported as:
Mean · Micromoles per liter
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate
Micromoles per literGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
Bilirubin, ON IV TREATMENT/DAY 2-1.9 ± 3.22-1.3 ± 2.87-2.4 ± 3.34
Bilirubin, ON IV TREATMENT/DAY 3-2.8 ± 4.42-1.0 ± 3.61-2.2 ± 2.73
Bilirubin, ON IV TREATMENT/DAY 4—-4.0 ± NA—
Bilirubin, ON IV TREATMENT/DAY 5-2.8 ± 4.64-4.0 ± 2.53—
Bilirubin, ON IV TREATMENT/DAY 70.0 ± 0.0-4.0 ± 0.00—
Bilirubin, ORAL - FIRST DAY-1.9 ± 3.87-1.7 ± 3.12-2.4 ± 2.69
Bilirubin, ORAL - DAY 7-10-0.9 ± 4.17-0.7 ± 2.49-1.7 ± 2.55
Bilirubin, POST THERAPY DAY 12-18-1.0 ± 4.35-0.5 ± 3.25-1.4 ± 3.83
Bilirubin, FOLLOW UP DAY 21-280.0 ± 8.720.0 ± 4.69-1.3 ± 6.11
Bilirubin, POST DOSE DAY 3-10-2.0 ± NA——
Creatinine, ON IV TREATMENT/DAY 23.45 ± 11.885-2.33 ± 19.8860.66 ± 8.711
Creatinine, ON IV TREATMENT/DAY 31.30 ± 10.462-5.35 ± 28.787-3.93 ± 12.123
Creatinine, ON IV TREATMENT/DAY 4—-1.70 ± NA—
Creatinine, ON IV TREATMENT/DAY 5-0.91 ± 10.5417.37 ± 8.704—
Creatinine, ON IV TREATMENT/DAY 78.40 ± 10.6076.65 ± 8.132—
Creatinine, ORAL - FIRST DAY4.22 ± 11.115-3.78 ± 27.5982.37 ± 10.268
Creatinine, ORAL - DAY 7-104.65 ± 9.9300.72 ± 30.6594.13 ± 9.518
Creatinine, POST THERAPY DAY 12-183.82 ± 10.6412.93 ± 26.4192.08 ± 9.293
Creatinine, FOLLOW UP DAY 21-289.92 ± 12.289-1.80 ± 2.8462.70 ± NA
Creatinine, POST DOSE DAY 3-10-2.70 ± NA——
Direct Bilirubin, ON IV TREATMENT/DAY 2-0.3 ± 2.09-0.6 ± 1.79-1.1 ± 2.28
Direct Bilirubin, ON IV TREATMENT/DAY 3-0.2 ± 2.33-0.7 ± 1.83-1.3 ± 2.24
Direct Bilirubin, ON IV TREATMENT/DAY 4—-2.0 ± NA—
Direct Bilirubin, ON IV TREATMENT/DAY 5-1.0 ± 1.94-0.7 ± 2.73—
Direct Bilirubin, ON IV TREATMENT/DAY 7-1.0 ± 1.41-3.0 ± 1.41—
Direct Bilirubin, ORAL - FIRST DAY-0.4 ± 2.15-0.2 ± 2.19-1.0 ± 2.08
Direct Bilirubin, ORAL - DAY 7-100.0 ± 1.950.0 ± 2.10-1.0 ± 2.16
Direct Bilirubin, POST THERAPY DAY 12-18-0.3 ± 2.020.0 ± 1.68-1.2 ± 2.03
Direct Bilirubin, FOLLOW UP DAY 21-281.5 ± 5.000.5 ± 1.910.0 ± NA
Direct Bilirubin, POST DOSE DAY 3-100.0 ± NA——
Urate, ON IV TREATMENT/DAY 21.2 ± 44.16-11.7 ± 42.46-17.1 ± 50.43
Urate, ON IV TREATMENT/DAY 34.2 ± 66.335.7 ± 52.02-14.4 ± 97.10
Urate, ON IV TREATMENT/DAY 4—60.0 ± NA—
Urate, ON IV TREATMENT/DAY 526.0 ± 89.4746.7 ± 50.86—
Urate, ON IV TREATMENT/DAY 710.0 ± 169.7190.0 ± 28.28—
Urate, ORAL - FIRST DAY16.3 ± 52.462.9 ± 67.26-1.3 ± 67.71
Urate, ORAL - DAY 7-1051.6 ± 55.3167.0 ± 69.7955.2 ± 65.32
Urate, POST THERAPY DAY 12-1860.8 ± 73.8849.4 ± 83.2445.3 ± 60.31
Urate, FOLLOW UP DAY 21-287.5 ± 80.1610.0 ± 102.31140.0 ± NA
Urate, POST DOSE DAY 3-1070.0 ± NA——
SecondaryChange From Baseline in Clinical Chemistry Parameters: Calcium, Carbon Dioxide, Chloride, Glucose, Magnesium, Potassium, Sodium and Urea

Blood samples for assessment of clinical chemistry parameters of calcium, carbon dioxide, chloride, glucose, magnesium, potassium, sodium and urea was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.

Time frame:
Baseline (Day 1) up to Day 28
Reported as:
Mean · Millimole per liter
Change From Baseline in Clinical Chemistry Parameters: Calcium, Carbon Dioxide, Chloride, Glucose, Magnesium, Potassium, Sodium and Urea
Millimole per literGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
Calcium, ON IV TREATMENT/DAY 2-0.041 ± 0.1095-0.018 ± 0.1227-0.048 ± 0.1221
Calcium, ON IV TREATMENT/DAY 3-0.007 ± 0.17320.019 ± 0.1247-0.009 ± 0.1289
Calcium, ON IV TREATMENT/DAY 4—-0.180 ± NA—
Calcium, ON IV TREATMENT/DAY 50.024 ± 0.1313-0.007 ± 0.1440—
Calcium, ON IV TREATMENT/DAY 70.080 ± NA0.040 ± 0.2263—
Calcium, ORAL - FIRST DAY0.042 ± 0.11520.022 ± 0.12450.018 ± 0.0908
Calcium, ORAL - DAY 7-100.093 ± 0.13730.064 ± 0.10630.030 ± 0.1231
Calcium, POST THERAPY DAY 12-180.083 ± 0.14400.087 ± 0.13630.047 ± 0.1239
Calcium, FOLLOW UP DAY 21-280.090 ± 0.16850.060 ± 0.06730.060 ± NA
Calcium, POST DOSE DAY 3-10-0.040 ± NA——
Carbon Dioxide, ON IV TREATMENT/DAY 2-0.5 ± 2.87-0.3 ± 2.460.1 ± 2.49
Carbon Dioxide, ON IV TREATMENT/DAY 3-0.5 ± 3.34-0.6 ± 2.710.4 ± 2.19
Carbon Dioxide, ON IV TREATMENT/DAY 4—1.0 ± NA—
Carbon Dioxide, ON IV TREATMENT/DAY 50.1 ± 4.280.7 ± 3.39—
Carbon Dioxide, ON IV TREATMENT/DAY 76.0 ± NA2.5 ± 2.12—
Carbon Dioxide, ORAL - FIRST DAY-0.5 ± 3.140.1 ± 2.55-0.4 ± 2.97
Carbon Dioxide, ORAL - DAY 7-10-0.5 ± 2.430.4 ± 2.87-0.2 ± 3.09
Carbon Dioxide, POST THERAPY DAY 12-18-0.3 ± 2.83-0.1 ± 3.321.0 ± 1.73
Carbon Dioxide, FOLLOW UP DAY 21-28-1.5 ± 3.322.3 ± 1.891.0 ± NA
Carbon Dioxide, POST DOSE DAY 3-10-4.0 ± NA——
Chloride, ON IV TREATMENT/DAY 22.1 ± 2.321.3 ± 2.922.4 ± 2.98
Chloride, ON IV TREATMENT/DAY 32.3 ± 2.921.4 ± 2.782.1 ± 4.04
Chloride, ON IV TREATMENT/DAY 4—-1.0 ± NA—
Chloride, ON IV TREATMENT/DAY 52.9 ± 2.730.5 ± 1.05—
Chloride, ON IV TREATMENT/DAY 7-0.5 ± 0.710.5 ± 0.71—
Chloride, ORAL - FIRST DAY1.4 ± 2.520.4 ± 2.701.1 ± 3.13
Chloride, ORAL - DAY 7-100.8 ± 3.630.7 ± 2.231.2 ± 2.93
Chloride, POST THERAPY DAY 12-181.7 ± 2.751.6 ± 3.211.8 ± 2.95
Chloride, FOLLOW UP DAY 21-280.5 ± 4.93-3.0 ± 2.943.0 ± NA
Chloride, POST DOSE DAY 3-104.0 ± NA——
Glucose, ON IV TREATMENT/DAY 20.32 ± 1.973-0.31 ± 2.863-0.88 ± 2.462
Glucose, ON IV TREATMENT/DAY 30.40 ± 2.1440.48 ± 3.087-0.37 ± 2.384
Glucose, ON IV TREATMENT/DAY 4—6.60 ± NA—
Glucose, ON IV TREATMENT/DAY 5-0.51 ± 3.2571.92 ± 1.723—
Glucose, ON IV TREATMENT/DAY 7-2.65 ± 4.3133.70 ± 2.687—
Glucose, ORAL - FIRST DAY0.11 ± 2.1150.13 ± 2.926-0.04 ± 1.619
Glucose, ORAL - DAY 7-100.14 ± 1.6981.08 ± 3.066-0.46 ± 1.741
Glucose, POST THERAPY DAY 12-18-0.19 ± 1.7740.34 ± 2.719-0.84 ± 2.068
Glucose, FOLLOW UP DAY 21-28-0.38 ± 1.2841.95 ± 3.450-0.10 ± NA
Glucose, POST DOSE DAY 3-100.30 ± NA——
Magnesium, ON IV TREATMENT/DAY 2-0.013 ± 0.0682-0.017 ± 0.06880.004 ± 0.0865
Magnesium, ON IV TREATMENT/DAY 30.007 ± 0.0829-0.012 ± 0.05530.018 ± 0.0689
Magnesium, ON IV TREATMENT/DAY 4—0.000 ± NA—
Magnesium, ON IV TREATMENT/DAY 50.044 ± 0.0532-0.040 ± 0.0738—
Magnesium, ON IV TREATMENT/DAY 70.140 ± 0.0000-0.080 ± 0.0283—
Magnesium, ORAL - FIRST DAY-0.009 ± 0.0709-0.016 ± 0.05920.006 ± 0.0613
Magnesium, ORAL - DAY 7-100.006 ± 0.0810-0.007 ± 0.07080.021 ± 0.0659
Magnesium, POST THERAPY DAY 12-18-0.005 ± 0.08640.006 ± 0.0870-0.008 ± 0.0737
Magnesium, FOLLOW UP DAY 21-280.000 ± 0.1347-0.040 ± 0.02830.000 ± NA
Magnesium, POST DOSE DAY 3-10-0.040 ± NA——
Potassium, ON IV TREATMENT/DAY 20.15 ± 0.3980.07 ± 0.4810.22 ± 0.458
Potassium, ON IV TREATMENT/DAY 30.24 ± 0.3530.11 ± 0.4290.16 ± 0.433
Potassium, ON IV TREATMENT/DAY 4—-0.10 ± NA—
Potassium, ON IV TREATMENT/DAY 50.28 ± 0.5590.02 ± 0.183—
Potassium, ON IV TREATMENT/DAY 7—0.55 ± 0.495—
Potassium, ORAL - FIRST DAY0.36 ± 0.3740.20 ± 0.4680.27 ± 0.365
Potassium, ORAL - DAY 7-100.29 ± 0.4830.06 ± 0.4340.05 ± 0.533
Potassium, POST THERAPY DAY 12-180.28 ± 0.5430.06 ± 0.5730.22 ± 0.487
Potassium, FOLLOW UP DAY 21-281.03 ± 0.877-0.35 ± 0.9980.60 ± NA
Potassium, POST DOSE DAY 3-10-0.10 ± NA——
Sodium, ON IV TREATMENT/DAY 21.1 ± 2.340.9 ± 2.671.6 ± 1.93
Sodium, ON IV TREATMENT/DAY 31.2 ± 2.591.0 ± 2.651.4 ± 4.16
Sodium, ON IV TREATMENT/DAY 4—-3.0 ± NA—
Sodium, ON IV TREATMENT/DAY 52.8 ± 2.781.0 ± 2.90—
Sodium, ON IV TREATMENT/DAY 72.0 ± 2.830.0 ± 8.49—
Sodium, ORAL - FIRST DAY1.2 ± 2.550.3 ± 3.051.2 ± 2.54
Sodium, ORAL - DAY 7-100.8 ± 2.440.5 ± 2.901.3 ± 2.55
Sodium, POST THERAPY DAY 12-181.1 ± 2.531.4 ± 2.701.8 ± 2.93
Sodium, FOLLOW UP DAY 21-28-3.0 ± 2.71-2.3 ± 2.871.0 ± NA
Sodium, POST DOSE DAY 3-105.0 ± NA——
Urea, ON IV TREATMENT/DAY 2-0.11 ± 1.308-0.11 ± 1.189-0.58 ± 1.110
Urea, ON IV TREATMENT/DAY 3-0.12 ± 1.484-0.24 ± 1.715-0.61 ± 2.088
Urea, ON IV TREATMENT/DAY 4—-1.00 ± NA—
Urea, ON IV TREATMENT/DAY 5-0.50 ± 1.4140.42 ± 1.320—
Urea, ON IV TREATMENT/DAY 71.00 ± 2.121-0.25 ± 1.061—
Urea, ORAL - FIRST DAY-0.13 ± 1.360-0.56 ± 1.650-0.41 ± 1.379
Urea, ORAL - DAY 7-100.77 ± 1.5760.10 ± 1.9450.29 ± 1.586
Urea, POST THERAPY DAY 12-180.60 ± 1.5630.63 ± 1.437-0.03 ± 1.486
Urea, FOLLOW UP DAY 21-281.63 ± 2.0160.25 ± 1.041-1.00 ± NA
Urea, POST DOSE DAY 3-100.00 ± NA——
SecondaryChange From Baseline in Clinical Chemistry Parameters: Creatinine Clearance, Estimated

Blood samples for assessment of clinical chemistry parameter of estimated creatinine clearance was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.

Time frame:
Baseline (Day 1) up to Day 28
Reported as:
Mean · Milliliter per minute
Change From Baseline in Clinical Chemistry Parameters: Creatinine Clearance, Estimated
Milliliter per minuteGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
ON IV TREATMENT/DAY 2-6.8 ± 22.65-1.8 ± 17.47-1.7 ± 17.98
ON IV TREATMENT/DAY 3-4.8 ± 32.171.7 ± 30.023.8 ± 19.70
ON IV TREATMENT/DAY 4—5.0 ± NA—
ON IV TREATMENT/DAY 5-17.4 ± 59.39-14.5 ± 14.92—
ON IV TREATMENT/DAY 7-22.0 ± 29.70-9.5 ± 13.44—
ORAL - FIRST DAY-12.6 ± 32.53-1.1 ± 31.43-6.3 ± 16.45
ORAL - DAY 7-10-13.2 ± 29.04-9.7 ± 36.67-8.3 ± 16.53
POST THERAPY DAY 12-18-8.8 ± 28.55-10.4 ± 24.61-5.6 ± 12.72
FOLLOW UP DAY 21-28-13.7 ± 25.543.8 ± 5.74—
POST DOSE DAY 3-106.0 ± NA——
SecondaryEstradiol Values at Baseline

Blood samples for assessment of clinical chemistry parameter of estradiol was collected at Baseline (Day 1). No post-baseline values were reported.

Time frame:
Baseline (Day 1)
Reported as:
Mean · Picomole per liter
Estradiol Values at Baseline
Picomole per literGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
Estradiol Values at Baseline229.4 ± 196.66148.8 ± 153.5823.5 ± 23.33
SecondaryChange From Baseline in Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets

Blood samples for assessment of hematology parameters of basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils and platelets was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.

Time frame:
Baseline (Day 1) up to Day 28
Reported as:
Mean · Giga cells per liter
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets
Giga cells per literGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
Basophils, ON IV TREATMENT/DAY 20.000 ± 0.03300.003 ± 0.02200.007 ± 0.0216
Basophils, ON IV TREATMENT/DAY 3-0.003 ± 0.02620.003 ± 0.0217-0.014 ± 0.0305
Basophils, ON IV TREATMENT/DAY 4—-0.020 ± NA—
Basophils, ON IV TREATMENT/DAY 50.008 ± 0.02120.007 ± 0.0437—
Basophils, ON IV TREATMENT/DAY 70.013 ± 0.02060.000 ± NA—
Basophils, ON IV TREATMENT/DAY 10-0.020 ± NA——
Basophils, ORAL - FIRST DAY0.000 ± 0.03100.000 ± 0.0185-0.004 ± 0.0171
Basophils, ORAL - DAY 7-100.001 ± 0.02770.007 ± 0.02580.004 ± 0.0169
Basophils, POST THERAPY DAY 12-180.005 ± 0.03040.001 ± 0.02170.001 ± 0.0190
Basophils, FOLLOW UP DAY 21-280.016 ± 0.0114-0.020 ± NA-0.007 ± 0.0404
Basophils, POST DOSE DAY 3-100.040 ± NA——
Eosinophils, ON IV TREATMENT/DAY 20.021 ± 0.15970.055 ± 0.14140.052 ± 0.0744
Eosinophils, ON IV TREATMENT/DAY 30.010 ± 0.14050.024 ± 0.14740.016 ± 0.0995
Eosinophils, ON IV TREATMENT/DAY 4—0.250 ± NA—
Eosinophils, ON IV TREATMENT/DAY 50.026 ± 0.08260.025 ± 0.1245—
Eosinophils, ON IV TREATMENT/DAY 70.055 ± 0.17230.040 ± NA—
Eosinophils, ON IV TREATMENT/DAY 100.010 ± NA——
Eosinophils, ORAL - FIRST DAY0.013 ± 0.14430.051 ± 0.20010.027 ± 0.0927
Eosinophils, ORAL - DAY 7-100.014 ± 0.14920.001 ± 0.13910.052 ± 0.1066
Eosinophils, POST THERAPY DAY 12-18-0.017 ± 0.11680.011 ± 0.13200.050 ± 0.1298
Eosinophils, FOLLOW UP DAY 21-28-0.004 ± 0.07160.000 ± NA0.060 ± 0.0436
Eosinophils, POST DOSE DAY 3-100.360 ± NA——
Leukocytes, ON IV TREATMENT/DAY 2-1.39 ± 2.722-1.35 ± 2.251-1.47 ± 2.086
Leukocytes, ON IV TREATMENT/DAY 3-2.04 ± 3.091-1.80 ± 2.692-2.94 ± 4.222
Leukocytes, ON IV TREATMENT/DAY 4—-7.10 ± NA—
Leukocytes, ON IV TREATMENT/DAY 5-2.49 ± 4.376-2.57 ± 1.402—
Leukocytes, ON IV TREATMENT/DAY 7-4.55 ± 5.108-2.90 ± NA—
Leukocytes, ON IV TREATMENT/DAY 10-11.20 ± NA——
Leukocytes, ORAL - FIRST DAY-1.31 ± 2.959-2.32 ± 2.527-1.69 ± 2.641
Leukocytes, ORAL - DAY 7-10-1.08 ± 2.482-1.91 ± 2.299-1.67 ± 2.637
Leukocytes, POST THERAPY DAY 12-18-2.15 ± 3.053-2.20 ± 2.464-2.25 ± 3.152
Leukocytes, FOLLOW UP DAY 21-28-2.06 ± 2.428-5.70 ± NA-3.23 ± 5.877
Leukocytes, POST DOSE DAY 3-10-12.60 ± NA——
Lymphocytes, ON IV TREATMENT/DAY 20.019 ± 0.61370.009 ± 0.50470.358 ± 0.7229
Lymphocytes, ON IV TREATMENT/DAY 30.263 ± 0.55740.094 ± 0.35040.129 ± 0.5742
Lymphocytes, ON IV TREATMENT/DAY 4—0.790 ± NA—
Lymphocytes, ON IV TREATMENT/DAY 50.288 ± 0.69180.075 ± 0.5417—
Lymphocytes, ON IV TREATMENT/DAY 70.705 ± 0.52910.200 ± NA—
Lymphocytes, ON IV TREATMENT/DAY 101.230 ± NA——
Lymphocytes, ORAL - FIRST DAY0.002 ± 0.6844-0.050 ± 0.73430.247 ± 0.8342
Lymphocytes, ORAL - DAY 7-100.222 ± 0.65920.204 ± 0.71310.284 ± 0.6655
Lymphocytes, POST-THERAPY DAY 12-180.179 ± 0.71220.028 ± 0.65880.184 ± 0.5295
Lymphocytes, FOLLOW UP DAY 21-280.326 ± 0.3564-0.020 ± NA0.097 ± 0.2743
Lymphocytes, POST DOSE DAY 3-100.850 ± NA——
Monocytes, ON IV TREATMENT/DAY 2-0.054 ± 0.1938-0.030 ± 0.2160-0.011 ± 0.2524
Monocytes, ON IV TREATMENT/DAY 3-0.002 ± 0.2326-0.133 ± 0.2330-0.219 ± 0.5008
Monocytes, ON IV TREATMENT/DAY 4—-0.280 ± NA—
Monocytes, ON IV TREATMENT/DAY 5-0.114 ± 0.2056-0.243 ± 0.2448—
Monocytes, ON IV TREATMENT/DAY 70.022 ± 0.3231-0.170 ± NA—
Monocytes, ON IV TREATMENT/DAY 10-0.240 ± NA——
Monocytes, ORAL - FIRST DAY-0.076 ± 0.2069-0.099 ± 0.2379-0.154 ± 0.2919
Monocytes, ORAL - DAY 7-10-0.014 ± 0.2030-0.067 ± 0.1690-0.070 ± 0.3348
Monocytes, POST THERAPY DAY 12-18-0.077 ± 0.1442-0.130 ± 0.2240-0.133 ± 0.3065
Monocytes, FOLLOW UP DAY 21-280.018 ± 0.29690.050 ± NA-0.347 ± 0.7050
Monocytes, POST DOSE DAY 3-100.280 ± NA——
Neutrophils, ON IV TREATMENT/DAY 2-1.373 ± 2.7464-1.395 ± 2.4280-1.873 ± 2.0729
Neutrophils, ON IV TREATMENT/DAY 3-2.324 ± 3.2252-1.789 ± 2.6403-2.854 ± 3.6332
Neutrophils, ON IV TREATMENT/DAY 4—-7.880 ± NA—
Neutrophils, ON IV TREATMENT/DAY 5-2.712 ± 4.5024-2.445 ± 0.9370—
Neutrophils, ON IV TREATMENT/DAY 7-5.403 ± 5.1790-2.910 ± NA—
Neutrophils, ON IV TREATMENT/DAY 10-12.250 ± NA——
Neutrophils, ORAL - FIRST DAY-1.244 ± 3.0855-2.229 ± 2.6921-1.802 ± 2.5066
Neutrophils, ORAL - DAY 7-10-1.363 ± 2.4532-2.068 ± 2.3963-1.930 ± 2.7752
Neutrophils, POST THERAPY DAY 12-18-2.243 ± 3.2754-2.111 ± 2.6465-2.346 ± 3.0470
Neutrophils, FOLLOW UP DAY 21-28-2.436 ± 2.5072-5.770 ± NA-3.007 ± 5.4347
Neutrophils, POST DOSE DAY 3-10-14.050 ± NA——
Platelets, ON IV TREATMENT/DAY 25.6 ± 37.646.3 ± 41.11-6.7 ± 57.38
Platelets, ON IV TREATMENT/DAY 35.8 ± 44.943.1 ± 41.89-0.6 ± 19.64
Platelets, ON IV TREATMENT/DAY 4—-30.0 ± NA—
Platelets, ON IV TREATMENT/DAY 543.7 ± 78.7821.3 ± 33.02—
Platelets, ON IV TREATMENT/DAY 777.8 ± 107.48-9.0 ± NA—
Platelets, ON IV TREATMENT/DAY 10159.0 ± NA——
Platelets, ORAL - FIRST DAY44.0 ± 74.120.1 ± 73.3611.6 ± 52.46
Platelets, ORAL - DAY 7-1022.7 ± 55.1133.9 ± 95.6322.0 ± 63.18
Platelets, POST THERAPY DAY 12-1817.5 ± 76.722.9 ± 88.150.6 ± 56.26
Platelets, FOLLOW UP DAY 21-2821.0 ± 26.44-92.0 ± NA-23.3 ± 62.93
Platelets, POST DOSE DAY 3-10148.0 ± NA——
SecondaryChange From Baseline in Hematology Parameters: Erythrocyte Mean Corpuscular Hemoglobin Concentration (EMCHC) and Hemoglobin

Blood samples for assessment of hematology parameters of EMCHC and hemoglobin was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.

Time frame:
Baseline (Day 1) up to Day 28
Reported as:
Mean · Gram per liter
Change From Baseline in Hematology Parameters: Erythrocyte Mean Corpuscular Hemoglobin Concentration (EMCHC) and Hemoglobin
Gram per literGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
EMCHC, ON IV TREATMENT/DAY 21.2 ± 6.082.0 ± 6.900.1 ± 6.94
EMCHC, ON IV TREATMENT/DAY 3-0.4 ± 6.642.9 ± 7.672.9 ± 7.90
EMCHC, ON IV TREATMENT/DAY 4—0.0 ± NA—
EMCHC, ON IV TREATMENT/DAY 5-4.3 ± 7.515.8 ± 10.85—
EMCHC, ON IV TREATMENT/DAY 72.8 ± 9.606.0 ± NA—
EMCHC, ON IV TREATMENT/DAY 10-6.0 ± NA——
EMCHC, ORAL - FIRST DAY1.2 ± 8.080.9 ± 8.231.1 ± 6.13
EMCHC, ORAL - DAY 7-102.8 ± 5.552.1 ± 7.062.1 ± 8.46
EMCHC, POST THERAPY DAY 12-181.6 ± 6.492.1 ± 6.830.6 ± 7.93
EMCHC, FOLLOW UP DAY 21-285.6 ± 10.810.0 ± NA8.3 ± 13.32
EMCHC, POST DOSE DAY 3-1021.0 ± NA——
Hemoglobin, ON IV TREATMENT/DAY 2-3.0 ± 9.04-1.2 ± 9.10-4.0 ± 8.79
Hemoglobin, ON IV TREATMENT/DAY 3-2.2 ± 10.95-2.2 ± 11.13-1.6 ± 8.22
Hemoglobin, ON IV TREATMENT/DAY 4—-8.0 ± NA—
Hemoglobin, ON IV TREATMENT/DAY 5-4.7 ± 10.27-8.0 ± 13.93—
Hemoglobin, ON IV TREATMENT/DAY 7-9.8 ± 7.803.0 ± NA—
Hemoglobin, ON IV TREATMENT/DAY 10-24.0 ± NA——
Hemoglobin, ORAL - FIRST DAY4.2 ± 9.42-0.9 ± 12.20-1.0 ± 8.20
Hemoglobin, ORAL - DAY 7-103.9 ± 11.181.8 ± 9.74-0.6 ± 7.45
Hemoglobin, POST THERAPY DAY 12-183.8 ± 10.182.2 ± 9.02-0.1 ± 10.85
Hemoglobin, FOLLOW UP DAY 21-288.4 ± 5.50-7.0 ± NA3.0 ± 15.87
Hemoglobin, POST DOSE DAY 3-10-1.0 ± NA——
SecondaryChange From Baseline in Hematology Parameters: Erythrocyte Mean Corpuscular Hemoglobin (EMCH)

Blood samples for assessment of hematology parameter of EMCH was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.

Time frame:
Baseline (Day 1) up to Day 28
Reported as:
Mean · Picograms
Change From Baseline in Hematology Parameters: Erythrocyte Mean Corpuscular Hemoglobin (EMCH)
PicogramsGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
ON IV TREATMENT/DAY 20.11 ± 0.4130.04 ± 0.386-0.07 ± 0.354
ON IV TREATMENT/DAY 30.00 ± 0.2780.05 ± 0.495-0.03 ± 0.374
ON IV TREATMENT/DAY 4—-0.40 ± NA—
ON IV TREATMENT/DAY 5-0.19 ± 0.3250.12 ± 0.319—
ON IV TREATMENT/DAY 70.30 ± 0.2940.20 ± NA—
ON IV TREATMENT/DAY 10-0.20 ± NA——
ORAL - FIRST DAY0.08 ± 0.408-0.01 ± 0.389-0.14 ± 0.333
ORAL - DAY 7-100.01 ± 0.290-0.03 ± 0.390-0.06 ± 0.438
POST THERAPY DAY 12-18-0.04 ± 0.3890.01 ± 0.366-0.08 ± 0.709
FOLLOW UP DAY 21-280.06 ± 0.483-0.40 ± NA1.20 ± 1.735
POST DOSE DAY 3-100.10 ± NA——
SecondaryChange From Baseline in Hematology Parameters: Erythrocyte Mean Corpuscular Volume (EMCV)

Blood samples for assessment of hematology parameter of EMCV was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.

Time frame:
Baseline (Day 1) up to Day 28
Reported as:
Mean · Femtoliter
Change From Baseline in Hematology Parameters: Erythrocyte Mean Corpuscular Volume (EMCV)
FemtoliterGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
ON IV TREATMENT/DAY 20.0 ± 1.73-0.4 ± 1.56-0.1 ± 1.90
ON IV TREATMENT/DAY 30.0 ± 1.61-0.6 ± 1.63-0.9 ± 1.96
ON IV TREATMENT/DAY 4—-2.0 ± NA—
ON IV TREATMENT/DAY 50.7 ± 2.06-1.0 ± 2.68—
ON IV TREATMENT/DAY 70.0 ± 3.65-1.0 ± NA—
ON IV TREATMENT/DAY 101.0 ± NA——
ORAL - FIRST DAY0.0 ± 1.96-0.3 ± 2.11-0.7 ± 1.66
ORAL - DAY 7-10-0.8 ± 1.52-0.6 ± 1.50-0.9 ± 1.77
POST THERAPY DAY 12-18-0.6 ± 1.76-0.5 ± 1.59-0.5 ± 1.68
FOLLOW UP DAY 21-28-1.6 ± 1.82-2.0 ± NA2.3 ± 3.21
POST DOSE DAY 3-10-7.0 ± NA——
SecondaryChange From Baseline in Hematology Parameters: Erythrocytes

Blood samples for assessment of hematology parameter of erythrocyte was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.

Time frame:
Baseline (Day 1) up to Day 28
Reported as:
Mean · Trillion cells per liter
Change From Baseline in Hematology Parameters: Erythrocytes
Trillion cells per literGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
ON IV TREATMENT/DAY 2-0.14 ± 0.332-0.04 ± 0.340-0.12 ± 0.345
ON IV TREATMENT/DAY 3-0.09 ± 0.430-0.06 ± 0.430-0.07 ± 0.320
ON IV TREATMENT/DAY 4—-0.30 ± NA—
ON IV TREATMENT/DAY 5-0.14 ± 0.373-0.28 ± 0.475—
ON IV TREATMENT/DAY 7-0.35 ± 0.2380.10 ± NA—
ON IV TREATMENT/DAY 10-0.80 ± NA——
ORAL - FIRST DAY0.12 ± 0.362-0.01 ± 0.420-0.01 ± 0.317
ORAL - DAY 7-100.12 ± 0.4000.07 ± 0.383-0.01 ± 0.284
POST THERAPY DAY 12-180.13 ± 0.3600.07 ± 0.3460.02 ± 0.416
FOLLOW UP DAY 21-280.26 ± 0.182-0.20 ± NA-0.03 ± 0.351
POST DOSE DAY 3-100.00 ± NA——
SecondaryChange From Baseline in Hematology Parameters: Hematocrit

Blood samples for assessment of hematology parameter of hematocrit was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.

Time frame:
Baseline (Day 1) up to Day 28
Reported as:
Mean · Ratio
Change From Baseline in Hematology Parameters: Hematocrit
RatioGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
ON IV TREATMENT/DAY 2-0.0111 ± 0.03004-0.0065 ± 0.03316-0.0125 ± 0.03152
ON IV TREATMENT/DAY 3-0.0066 ± 0.03683-0.0099 ± 0.03922-0.0073 ± 0.02536
ON IV TREATMENT/DAY 4—-0.0260 ± NA—
ON IV TREATMENT/DAY 5-0.0101 ± 0.03166-0.0322 ± 0.04462—
ON IV TREATMENT/DAY 7-0.0353 ± 0.018730.0020 ± NA—
ON IV TREATMENT/DAY 10-0.0690 ± NA——
ORAL - FIRST DAY0.0112 ± 0.03422-0.0041 ± 0.04091-0.0043 ± 0.02854
ORAL - DAY 7-100.0080 ± 0.036740.0027 ± 0.03459-0.0040 ± 0.02840
POST THERAPY DAY 12-180.0100 ± 0.033400.0039 ± 0.02846-0.0006 ± 0.04085
FOLLOW UP DAY 21-280.0178 ± 0.01699-0.0220 ± NA0.0033 ± 0.03988
POST DOSE DAY 3-10-0.0320 ± NA——
SecondaryNumber of Participants With Abnormal Urinalysis Dipstick Results

Samples for urinalysis assessment was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28 for Glucose, Ketones, Occult Blood, Protein and pH. Participants with abnormal urinalysis result was reported.

Time frame:
Up to day 28
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Urinalysis Dipstick Results
ParticipantsGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
Glucose, BASELINE/DAY 1, Trace121
Glucose, BASELINE/DAY 1, 1+111
Glucose, BASELINE/DAY 1, 3+121
Glucose, ON IV TREATMENT/DAY 2, Trace100
Glucose, ON IV TREATMENT/DAY 2, 1+002
Glucose, ON IV TREATMENT/DAY 2, 3+321
Glucose, ON IV TREATMENT/DAY 3, 2+110
Glucose, ON IV TREATMENT/DAY 3, 3+110
Glucose, ON IV TREATMENT/DAY 5, 2+10—
Glucose, ON IV TREATMENT/DAY 7, 2+10—
Glucose, ORAL - FIRST DAY, Trace010
Glucose, ORAL - FIRST DAY, 1+100
Glucose, ORAL - FIRST DAY, 3+120
Glucose, ORAL - DAY 7-10, Trace100
Glucose, ORAL - DAY 7-10, 1+010
Glucose, ORAL - DAY 7-10, 2+010
Glucose, ORAL - DAY 7-10, 3+020
Glucose, POST THERAPY DAY 12-18, Trace300
Glucose, POST THERAPY DAY 12-18, 1+010
Glucose, POST THERAPY DAY 12-18, 3+030
Ketones, BASELINE/DAY 1, Trace836
Ketones, BASELINE/DAY 1, 1+110
Ketones, BASELINE/DAY 1, 3+020
Ketones, ON IV TREATMENT/DAY 2, Trace431
Ketones, ON IV TREATMENT/DAY 2, 1+210
Ketones, ON IV TREATMENT/DAY 2, 3+001
Ketones, ON IV TREATMENT/DAY 3, Trace502
Ketones, ORAL - FIRST DAY, Trace312
Ketones, ORAL - FIRST DAY, 2+100
Ketones, ORAL - DAY 7-10, Trace633
Ketones, POST THERAPY DAY 12-18, Trace862
Occult Blood, BASELINE/DAY 1, Trace311
Occult Blood, BASELINE/DAY 1, 1+401
Occult Blood, BASELINE/DAY 1, 2+110
Occult Blood, BASELINE/DAY 1, 3+401
Occult Blood, ON IV TREATMENT/DAY 2, Trace301
Occult Blood, ON IV TREATMENT/DAY 2, 1+100
Occult Blood, ON IV TREATMENT/DAY 2, 2+002
Occult Blood, ON IV TREATMENT/DAY 2, 3+110
Occult Blood, ON IV TREATMENT/DAY 3, Trace010
Occult Blood, ON IV TREATMENT/DAY 3, 3+001
Occult Blood, ON IV TREATMENT/DAY 5, Trace20—
Occult Blood, ON IV TREATMENT/DAY 7, Trace10—
Occult Blood, ORAL - FIRST DAY, Trace211
Occult Blood, ORAL - FIRST DAY, 1+310
Occult Blood, ORAL - FIRST DAY, 2+100
Occult Blood, ORAL - FIRST DAY, 3+010
Occult Blood, ORAL - DAY 7-10, Trace101
Occult Blood, ORAL - DAY 7-10, 2+101
Occult Blood, ORAL - DAY 7-10, 3+001
Occult Blood, POST THERAPY DAY 12-18, Trace111
Occult Blood, POST THERAPY DAY 12-18, 1+110
Occult Blood, POST THERAPY DAY 12-18, 2+110
Occult Blood, POST THERAPY DAY 12-18, 3+101
Protein, BASELINE/DAY 1, Trace755
Protein, BASELINE/DAY 1, 1+645
Protein, BASELINE/DAY 1, 2+101
Protein, BASELINE/DAY 1, 3+100
Protein, ON IV TREATMENT/DAY 2, Trace464
Protein, ON IV TREATMENT/DAY 2, 1+774
Protein, ON IV TREATMENT/DAY 3, Trace430
Protein, ON IV TREATMENT/DAY 3, 1+323
Protein, ON IV TREATMENT/DAY 3, 2+100
Protein, ON IV TREATMENT/DAY 5, Trace20—
Protein, ON IV TREATMENT/DAY 5, 1+01—
Protein, ORAL - FIRST DAY, Trace231
Protein, ORAL - FIRST DAY, 1+042
Protein, ORAL - FIRST DAY, 2+100
Protein, ORAL - DAY 7-10, Trace746
Protein, ORAL - DAY 7-10, 1+654
Protein, ORAL - DAY 7-10, 2+111
Protein, POST THERAPY DAY 12-18, Trace862
Protein, POST THERAPY DAY 12-18, 1+343
Protein, POST THERAPY DAY 12-18, 2+010
pH, Post-Baseline Maximum, 8.5100

Adverse events

Collected over AEs were collected up to follow-up (Day 28).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gepotidacin 750 mg q12h0/58 (0%)1/58 (1.7%)30/58 (51.7%)
Gepotidacin 1000 mg q12h1/39 (2.6%)1/39 (2.6%)20/39 (51.3%)
Gepotidacin 1000 mg q8h0/25 (0%)0/25 (0%)14/25 (56%)
Most frequent serious events
Most frequent serious events
EventGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
Septic shockInfections and infestations0/581/390/25
CellulitisInfections and infestations1/580/390/25
Most frequent other events
Showing 10 of 11
Most frequent other events
EventGepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8h
NauseaGastrointestinal disorders12/589/394/25
DiarrhoeaGastrointestinal disorders5/586/395/25
VomitingGastrointestinal disorders3/582/393/25
HeadacheNervous system disorders6/581/390/25
FlatulenceGastrointestinal disorders3/581/392/25
Gastrooesophageal reflux diseaseGastrointestinal disorders1/580/392/25
Alanine aminotransferase increasedInvestigations4/583/392/25
Aspartate aminotransferase increasedInvestigations3/583/391/25
Gamma-glutamyltransferase increasedInvestigations3/583/390/25
Pruritus generalisedSkin and subcutaneous tissue disorders1/583/390/25

Baseline characteristics

mITT population: those participants who received study treatment

Age, Continuous
Age, Continuous(Years)Gepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8hTotal
Mean44.3 ± 11.3544.6 ± 10.7645.8 ± 12.6444.7 ± 11.36
Sex: Female, Male
Sex: Female, Male(Participants)Gepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8hTotal
Female1812535
Male40272087
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Gepotidacin 750 mg q12hGepotidacin 1000 mg q12hGepotidacin 1000 mg q8hTotal
American Indian or Alaska Native1102
Asian0011
Native Hawaiian or Other Pacific Islander1001
Black or African American1203
White553624115
More than one race0000
Unknown or Not Reported0000
08

Study locations

30 sites
  • GSK Investigational Site
    Phoenix, Arizona 85021, United States
  • GSK Investigational Site
    Anaheim, California 92804, United States
  • GSK Investigational Site
    Chula Vista, California 91942, United States
  • GSK Investigational Site
    La Mesa, California 91942, United States
  • GSK Investigational Site
    Oceanside, California 92056, United States
  • GSK Investigational Site
    Sylmar, California 91342, United States
  • GSK Investigational Site
    Torrance, California 90502, United States
  • GSK Investigational Site
    Miramar, Florida 33027, United States
  • GSK Investigational Site
    West Palm Beach, Florida 33401, United States
  • GSK Investigational Site
    Augusta, Georgia 30909, United States
  • GSK Investigational Site
    Augusta, Georgia 30912, United States
  • GSK Investigational Site
    Council Bluffs, Iowa 51503, United States
  • GSK Investigational Site
    Hazard, Kentucky 41701, United States
  • GSK Investigational Site
    Zachary, Louisiana 70791, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55422, United States
  • GSK Investigational Site
    Carriere, Mississippi 39426, United States
  • GSK Investigational Site
    Jackson, Mississippi 39216-4505, United States
  • GSK Investigational Site
    Butte, Montana 59701, United States
  • GSK Investigational Site
    Lincoln, Nebraska 68510, United States
  • GSK Investigational Site
    Las Vegas, Nevada 92120, United States
  • GSK Investigational Site
    Belleville, New Jersey 07109, United States
  • GSK Investigational Site
    Neptune City, New Jersey 07753, United States
  • GSK Investigational Site
    Albany, New York 12208, United States
  • GSK Investigational Site
    Brooklyn, New York 11215, United States
  • GSK Investigational Site
    Lima, Ohio 45801, United States
  • GSK Investigational Site
    Toledo, Ohio 43608, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15212, United States
  • GSK Investigational Site
    Channelview, Texas 77530, United States
  • GSK Investigational Site
    Houston, Texas 77024, United States
  • GSK Investigational Site
    Houston, Texas 77030, United States
09

References and documents

Publications

  • Scangarella-Oman NE, Ingraham KA, Tiffany CA, Tomsho L, Van Horn SF, Mayhew DN, Perry CR, Ashton TC, Dumont EF, Huang J, Brown JR, Miller LA. In Vitro Activity and Microbiological Efficacy of Gepotidacin from a Phase 2, Randomized, Multicenter, Dose-Ranging Study in Patients with Acute Bacterial Skin and Skin Structure Infections. Antimicrob Agents Chemother. 2020 Feb 21;64(3):e01302-19. doi: 10.1128/AAC.01302-19. Print 2020 Feb 21. PubMed 31818823 ↗
  • O'Riordan W, Tiffany C, Scangarella-Oman N, Perry C, Hossain M, Ashton T, Dumont E. Efficacy, Safety, and Tolerability of Gepotidacin (GSK2140944) in the Treatment of Patients with Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections. Antimicrob Agents Chemother. 2017 May 24;61(6):e02095-16. doi: 10.1128/AAC.02095-16. Print 2017 Jun. PubMed 28373199 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2014 to primary completion in Jun 2015, 15 months.

Results were first posted in Sep 2017, 2 years 2 months after primary completion. A results delay was requested in Oct 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2014
First posted
Jan 27, 2014
StartActual
Mar 24, 2014
Primary completionActual
Jun 29, 2015
CompletionActual
Jun 29, 2015
Results delay requested
Oct 12, 2015
Results first posted
Sep 21, 2017
Last update
Nov 17, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02045797
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jan 27, 2014
Start date
Mar 24, 2014
Primary completion
Jun 29, 2015
Completion
Jun 29, 2015
Results posted
Sep 21, 2017
Last update
Nov 17, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gepotidacin

Start the discussion